Platelet count independent treatment method for myelofibrosis - Patent Application 20070123633

Momelotinib addresses the limitations of current myelofibrosis treatments by maintaining platelet counts and improving symptoms in patients with myelofibrosis, including those at risk of thrombocytopenia, through its selective inhibition of JAK1, JAK2, and ACVR1, offering a stable therapeutic benefit.

JP7578585B2Active Publication Date: 2024-11-06GLAXO SMITHKLINE LLC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021509885
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-03
Filing Date
2019-08-21
Publication Date
2024-11-06
Estimated Expiration
2039-08-21

AI Technical Summary

Technical Problem

Current treatments for myelofibrosis, such as ruxolitinib, cause thrombocytopenia and are ineffective for 30% of patients, leading to dose reduction or discontinuation, and there is a need for alternative therapies that can manage symptoms and anemia without causing similar adverse effects.

Method used

Momelotinib, a potent and selective inhibitor of JAK1, JAK2, and ACVR1, is administered to maintain platelet counts above a threshold, reducing spleen size and improving symptoms in patients with myelofibrosis, including those with low platelet counts, without causing thrombocytopenia.

Benefits of technology

Momelotinib effectively reduces spleen size, improves total symptom score, and enhances transfusion independence in patients with myelofibrosis, particularly those at risk of thrombocytopenia, by maintaining stable platelet counts and providing symptomatic relief.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578585000023
    Figure 0007578585000023
  • Figure 0007578585000024
    Figure 0007578585000024
  • Figure 0007578585000025
    Figure 0007578585000025
Patent Text Reader

Abstract

Reanalysis of the SIMPLIFY 1 and 2 trial data indicates that MMB is effective in second-line treatment of JAKi-naive patients and RUX, providing benefits such as reducing splenomegaly, ameliorating myelofibrosis-related symptoms, and increasing transfusion independence in patients at risk for thrombocytopenia from underlying disease and RUX treatment. Accordingly, a method for treating myeloproliferative neoplasms (MPNs), such as myelofibrosis, is described. The method comprises administering a therapeutically effective amount of momelotinib, or a pharmaceutically acceptable salt thereof, to (i) myelofibrosis and (ii) 150×10 9 Also described are methods comprising administering a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof to a subject with myelofibrosis for multiple weeks, wherein the subject is assessed to maintain a platelet count above a predetermined threshold platelet count over the period.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 62 / 720,782, filed August 21, 2018, U.S. Provisional Patent Application No. 62 / 749,052, filed October 22, 2018, and U.S. Provisional Patent Application No. 62 / 774,752, filed December 3, 2018, each of which is incorporated by reference in its entirety herein. [Background technology]

[0002] Myelofibrosis (MF) is a disease that affects approximately 40,000-50,000 patients worldwide, of which 70-80% are classified as intermediate-risk to high-risk MF patients. The median survival of all patients with MF is approximately 6 years, but patients classified as intermediate-2 risk or high-risk MF have a significantly worse survival of 4 years and 2.25 years, respectively.

[0003] Myelofibrosis can arise de novo as primary MF (PMF) or from pre-existing myeloproliferative neoplasms (MPN), primarily polycythemia vera (PV) or essential thrombocythemia (ET). When these conditions reach an overtly fibrotic stage, they are virtually indistinguishable clinically.

[0004] The three major disease manifestations of MF are (1) anemia, often associated with thrombocytopenia or other cytopenias; (2) constitutional symptoms, such as fatigue, night sweats, fever, cachexia, bone pain, pruritus, and weight loss; and (3) organomegaly, primarily of the spleen, and less frequently of the liver, due to extramedullary hematopoiesis, which can cause common associated symptoms such as abdominal distension and pain, early satiety, dyspnea, and diarrhea.

[0005] Ruxolitinib (RUX) is a Janus kinase (JAK) inhibitor used to treat intermediate-risk and high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Ruxolitinib is currently used to treat approximately 70% of patients, but is not approved for patients with severe thrombocytopenia.

[0006] In addition, treatment with ruxolitinib can itself cause thrombocytopenia. In two phase 3 clinical trials of ruxolitinib, 100 × 10 9 ~200×10 9 / L platelet count is 200 × 10 9 Patients with entry platelet counts >50 × 10 / L had a higher incidence of grade 3 or 4 thrombocytopenia (17% vs. 7%). In patients who developed grade 3 or 4 thrombocytopenia, the median time to onset of thrombocytopenia was approximately 8 weeks. Thrombocytopenia generally resolved with dose reduction or dose interruption. 9 The median time to recovery of platelet counts above 1 / L was 14 days.

[0007] In clinical practice, thrombocytopenia during treatment is managed by reducing the dose or temporarily interrupting ruxolitinib treatment, with platelet transfusions as needed. After cessation of ruxolitinib, myeloproliferative neoplasms symptoms may return to pretreatment severity in as little as 7 days.

[0008] MF is a chronic, progressive, and always fatal disease. The current standard of care, ruxolitinib, cannot be administered to 30% of current patients. Ruxolitinib itself causes thrombocytopenia and anemia, leading to dose reduction or interruption and recurrence of symptoms. Most patients require additional treatment after ruxolitinib treatment.

[0009] Unfortunately, the recently approved JAK2 / FLT3 inhibitor fedratinib has a similar hematologic toxicity profile to ruxolitinib, with a 50 × 10 9It is only administered to patients with a baseline platelet count of ≥ 1 / L, with the dose reduced for grade 4 thrombocytopenia or other adverse events. As a result, despite the availability of ruxolitinib and fedratinib, there is a continuing need for additional treatments for this fatal disease. Summary of the Invention

[0010] Momelotinib (MMB) is a potent, selective, orally bioavailable small molecule inhibitor of JAK1, JAK2, and activin A receptor type I (ACVR1) that was developed for the treatment of myelofibrosis (MF). However, in two phase 3 clinical trials (SIMPLIFY-1 and -2, respectively) for the first- and second-line treatment of MF, MMB did not meet one of the predefined primary or secondary endpoints in each of these two clinical trials.

[0011] The SIMPLIFY-1 trial (NCT01969838) evaluated the efficacy and safety of MMB versus ruxolitinib (RUX) in patients with JAK inhibitor-naïve disease and at least 50 × 10 9 Patients with myelofibrosis with platelet counts of 0.01 mg / L were studied. Patients (N=432) with high-risk or intermediate-2-risk or symptomatic intermediate-1-risk myelofibrosis were treated with 200 mg MMB once daily or 20 mg RUX twice daily (or as labeled) for 24 weeks, after which all patients could receive open-label momelotinib. Efficacy was measured with the aim of demonstrating non-inferiority of MMB to RUX by splenic response, total symptom score (TSS), red blood cell transfusion rate, and transfusion independence or transfusion dependence. The primary endpoint was a reduction in spleen volume of at least 35% at 24 weeks compared with baseline.

[0012] The first analysis of the results of the SIMPLIFY-1 trial was reported by Mesa et al. (SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients with Myelofibrosis”, J. Clinical Oncology 2017,35(34):3844-3850). Their analysis of the SIMPLIFY-1 trial data showed that momelotinib was non-inferior to RUX for reducing spleen size in JAKi-naive patients, thus meeting the primary endpoint of the study. However, despite evidence of symptomatic benefit of momelotinib in symptomatic patients in that study, non-inferiority was not demonstrated for the secondary endpoint of total symptom score (TSS) response. MMB treatment was associated with an increased rate of transfusion independence, a decreased rate of transfusion dependence, and a decreased transfusion rate compared with RUX, all of which were nominally statistically significant.

[0013] The SIMPLIFY-2 trial (NCT02101268) investigated the efficacy and safety of MMB versus best available treatment (BAT) in anemic or thrombocytopenic subjects with myelofibrosis previously treated with ruxolitinib (RUX). There was no lower limit for the required baseline platelet count. Efficacy was measured by splenic response, total symptom score (TSS), red blood cell transfusion rate, and transfusion independence or transfusion dependence, with the goal of demonstrating superiority of MMB over BAT. The primary endpoint was a reduction in spleen volume of at least 35% at 24 weeks compared to baseline.

[0014] The first analysis of the results of the SIMPLIFY-2 trial was reported by Harrison et al. ("Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY2): a randomised, open-label, phase 3 trial." Lancet Haematol; Vol. 5, No. 2, February 2018, pp. e73-e81). Their analysis of the SIMPLIFY-2 trial data showed that momelotinib was not superior to the primary ruxolitinib BAT for reducing spleen size, and therefore the trial failed to meet its primary endpoint and formal hierarchical statistical testing was stopped.

[0015] Nominal statistical significance was observed for TSS response rate and transfusion independence rate vs. BAT. Reductions in transfusion dependency rate and transfusion burden were also noted. Initial analyses were complicated by the failure to mandate discontinuation of ruxolitinib prior to the initiation of randomized study treatment. By not including a mandatory washout from prior ruxolitinib, assessment of splenic response was unclear for subjects in either arm in this study. Additionally, patients enrolled in this study were not selected based on splenic progression on RUX.

[0016] We reanalyzed data from the SIMPLIFY-1 and SIMPLIFY-2 trials to demonstrate that momelotinib administration did not cause thrombocytopenia and therefore did not require dose reduction or interruption for thrombocytopenia, and that momelotinib reduced spleen size (SSR), improved total symptom score (TSS), and reduced splenic hepatitis C (H1C) by 150 × 10 per liter. 9We found that MMB was effective in improving transfusion independence in patients with platelet counts below 1 / L. Our reanalysis indicates that MMB is effective in JAKi-naïve patients and as second-line treatment for RUX, offering the benefits of reducing splenomegaly, ameliorating symptoms associated with myelofibrosis, and improving transfusion independence rates in a patient population with or at risk for thrombocytopenia from underlying disease and current standard of care.

[0017] Accordingly, the present disclosure describes a method of treating myeloproliferative neoplasms (MPNs), such as myelofibrosis. In some embodiments, the method comprises administering a therapeutically effective amount of momelotinib or a pharmacologic acceptable salt thereof to (i) myelofibrosis and (ii) 150×10 9 Also provided is a method of treating myeloproliferative neoplasms (MPNs), such as myelofibrosis, comprising administering a therapeutically effective stable dose of momelotinib, or a pharma- ceutically acceptable salt thereof, for a period of multiple weeks, wherein the subject is assessed as maintaining a platelet count above a pre-determined threshold platelet count during the treatment period. [Brief description of the drawings]

[0018] These and other features, aspects, and advantages of the present disclosure will become better understood with regard to the following description and the accompanying drawings.

[0019] [Figure 1] FIG. 1 shows a schematic diagram of the characteristics of myelofibrosis, a chronic myeloproliferative neoplasm (MPN). [Diagram 2]

[0023] Figure 1 is a schematic diagram showing three disease hallmarks of myelofibrosis and the percentage of patients who exhibit these features one year after initial diagnosis. See Tefferi A et al. Mayo Clin. Proc. 2012;87:25-33. [Diagram 3]Figure 1 shows a graph of survival rates for myelofibrosis patients with mild, moderate, and severe anemia vs. myelofibrosis patients without anemia, showing that anemia is an important prognostic factor. Baseline anemia: Mild = Hgb ≥ 10 g / dl but below the lower limit of normal; Intermediate = Hgb ≥ 8 g / dl to < 10 g / dl; Severe = Hgb < 8 g / dl or transfusion dependent. See, e.g., Nicolosi et al. Leukemia 2018 32(5):1189-1199. [Figure 4] FIG. 1 shows a schematic illustrating the pathway to anemia in myelofibrosis. [Figure 5A] We present the biological basis for the anemia benefit of momelotinib in subjects with myelofibrosis. ACVR1 and hepcidin: The iron metabolism pathway involves TGFβ superfamily receptors such as ACVR1. ACVR1 signals through Smads that activate the transcription of hepcidin (Figure 5A), and elevated hepcidin leads to decreased erythropoiesis (Figure 5B). Other therapeutic agents targeting the TGFβ superfamily include luspatercept and sotatercept. [Figure 5B] We present the biological basis for the anemia benefit of momelotinib in subjects with myelofibrosis. ACVR1 and hepcidin: The iron metabolism pathway involves TGFβ superfamily receptors such as ACVR1. ACVR1 signals through Smads that activate the transcription of hepcidin (Figure 5A), and elevated hepcidin leads to decreased erythropoiesis (Figure 5B). Other therapeutic agents targeting the TGFβ superfamily include luspatercept and sotatercept. [Figure 6] FIG. 1 is a schematic showing that momelotinib treatment ameliorates three hallmarks of myelofibrosis disease. [Figure 7]We show that momelotinib is a distinct JAK inhibitor (JAKi). Other JAKis have not consistently demonstrated a broad ability to address the needs of MF patients. Only momelotinib has robust splenic, symptomatic, and anemia benefits. Momelotinib has been studied in more than 20 Phase 1, 2, and 3 clinical trials, including dosing in more than 1,200 patients. More than 550 myelofibrosis patients have been treated, with several patients being treated for at least 7 years. Momelotinib is the only JAKi that can provide a variety of robust benefits in MF, such as splenic, symptomatic, and anemia, and is not associated with high rates of anemia and thrombocytopenia. [Figure 8A] A schematic diagram summarizing the parameters of two completed Phase 3 trials with momelotinib (MMB) treatment of myelofibrosis: SIMPLIFY-1 and SIMPLIFY-2 is shown. Figure 8A: SIMPLIFY-1 trial of MMB in a first-line population not previously treated with a JAKi. In SIMPLIFY-1, the goal was non-inferiority to ruxolitinib (RUX). Figure 8B: SIMPLIFY-2 trial in a second-line population of anemic or thrombocytopenic subjects previously treated with RUX. In SIMPLIFY-2, the goal was superior to best available treatment (BAT). [Figure 8B] A schematic diagram summarizing the parameters of two completed Phase 3 trials with momelotinib (MMB) treatment of myelofibrosis: SIMPLIFY-1 and SIMPLIFY-2 is shown. Figure 8A: SIMPLIFY-1 trial of MMB in a first-line population not previously treated with a JAKi. In SIMPLIFY-1, the goal was non-inferiority to ruxolitinib (RUX). Figure 8B: SIMPLIFY-2 trial in a second-line population of anemic or thrombocytopenic subjects previously treated with RUX. In SIMPLIFY-2, the goal was superior to best available treatment (BAT). [Figure 9]Graphs of baseline median and 24-week mean median symptom scores assessed as the 4-week average of daily symptom scores for the seven individual symptoms that make up the Total Symptom Score (TSS) in the SIMPLIFY1 study show that both momelotinib and ruxolitinib significantly improved all symptoms compared to baseline in a clinically comparable manner. Bar graph inset shows that baseline mean and median TSS were higher in the momelotinib group versus RUX. [Figure 10] Showing rapid and sustained hemoglobin improvement in patients following initiation of MMB, and similar rapid and sustained hemoglobin improvement in subjects randomized to ruxolitinib following momelotinib crossover after 24 weeks in SIMPLIFY11. [Figure 11] Figure 1 shows that momelotinib consistently reduced hepcidin after MMB administration. In addition to the sharp decline after administration, there was a gradual decline over the 24-week study period compared to baseline and pre-dose levels at enrollment. Translational Biology Phase 2 Study (N=41; GS-US-352-1672). [Figure 12] A schematic diagram of MMB exploratory translational biology research is shown. [Figure 13] FIG. 1 is an exemplary timeline of high levels of iron and hemoglobin following initiation of momelotinib treatment, supported by data from a translational biology Phase 2 study (N=41; GS-US-352-1672). [Figure 14] Graph showing increased iron and hemoglobin levels observed overall and in transfusion-independent responders (TI-R) to MMB treatment. Translational biology Phase 2 study (N=41; GS-US-352-1672). [Figure 15] FIG. 1 shows the X-ray powder diffraction (XRPD) of momelotinib dihydrochloride anhydrate Form IV. [Figure 16] FIG. 1 shows a differential scanning calorimetry (DSC) plot of momelotinib dihydrochloride anhydrate Form IV. [Figure 17]FIG. 1 shows a thermogravimetric analysis (TGA) of momelotinib dihydrochloride anhydrate Form IV. [Figure 18] FIG. 1 shows a dynamic vapor sorption (DVS) plot of momelotinib dihydrochloride anhydrate Form IV. [Figure 19] FIG. 1 shows the XRPD pattern of momelotinib dihydrochloride monohydrate form II. [Figure 20] FIG. 1 shows the XRPD pattern of momelotinib monohydrochloride anhydrate form I. [Figure 21] FIG. 1 shows the XRPD pattern of momelotinib monohydrochloride anhydrate Form III. [Figure 22] FIG. 1 shows a DSC plot of momelotinib dihydrochloride monohydrate Form II. [Figure 23] 1 shows a DSC plot of momelotinib monohydrochloride anhydrate Form I. [Figure 24] FIG. 1 shows a DSC plot of momelotinib monohydrochloride anhydrate Form III. [Diagram 25] 1 shows a TGA of momelotinib dihydrochloride monohydrate Form II. [Figure 26] 1 shows a TGA of momelotinib monohydrochloride anhydrate Form I. [Figure 27] 1 shows a TGA of momelotinib monohydrochloride anhydrate Form III. [Figure 28] FIG. 1 shows a DVS plot of momelotinib dihydrochloride monohydrate Form II. [Figure 29] Kaplan-Meier estimates of the proportion of patients not requiring red blood cell (RBC) transfusions during 24 weeks of RUX or MMB treatment in the SIMPLIFY-1 trial are shown. [Diagram 30] FIG. 1 is a schematic summarizing parameters of the MOMENTUM trial of myelofibrosis treatment with momelotinib (MMB). [Diagram 31] 1 shows a plot of the mean (± standard error) platelet counts in subjects with MMB versus RUX in the SIMPLIFY 1 study over the 24-week double-blind treatment phase. [Diagram 32]1 shows plots of mean (± standard error) platelet counts over time during the double-blind and open-label treatment phases for MMB versus RUX in the SIMPLIFY1 study (intent to treat (ITT)). [Diagram 33] 1 shows plots of mean (± standard error) platelet counts over time during the randomized and chronic treatment phases of the SIMPLIFY2 trial (ITT) for MMB versus best available therapy (BAT). [Diagram 34] 1 shows dose breakdown by treatment for treated patients during the first 24 weeks of the SIMPLIFY1 study, demonstrating the reduction in RUX dose and the relative stability of MMB dose levels during treatment. [Diagram 35] 1 shows dose stratification by treatment for treated patients during the first 24 weeks of the SIMPLIFY2 study, demonstrating the reduction in RUX dose and the relative stability of MMB dose levels during treatment. [Diagram 36] Graphs of the Spleen Response Rate (SRR) at Week 24 versus baseline platelet count subgroups for all MMB or control (i.e., RUX) patients treated in the SIMPLIFY1 study are shown. The horizontal bars on the graphs in Figures 36-47 represent the 95% confidence intervals of the mean response for all patients (all points). [Figure 37] 1 shows a graph of SRR versus baseline platelet count subgroups at Week 24 for symptomatic (e.g., baseline TSS ≧6) MMB or control (i.e., RUX) patients treated with the SIMPLIFY1 trial. [Figure 38] 1 shows a graph of SRR vs. baseline platelet count subgroups at Week 24 for symptomatic (e.g., baseline TSS ≧10) MMB or control (i.e., RUX) patients treated with the SIMPLIFY1 trial. [Figure 39] 1 shows a graph of total symptom score (TSS) at week 24 versus baseline platelet count subgroups for all MMB or control (i.e., RUX) patients treated in the SIMPLIFY1 trial. [Diagram 40]1 shows graphs of TSS vs. baseline platelet count subgroups at Week 24 for symptomatic (e.g., baseline TSS ≧6) MMB or control (i.e., RUX) patients treated with the SIMPLIFY1 trial. [Diagram 41] 1 shows graphs of TSS vs. baseline platelet count subgroups at Week 24 for symptomatic (e.g., baseline TSS ≧10) MMB or control (i.e., RUX) patients treated with the SIMPLIFY1 trial. [Diagram 42] 1 shows a graph of transfusion-dependent (TD) to transfusion-independent (TI) conversion rate at week 24 versus baseline platelet count subgroups for all MMB or control (i.e., RUX) patients treated with the SIMPLIFY1 trial. [Diagram 43] 1 shows a graph of TD to TI conversion rate at Week 24 versus baseline platelet count subgroups for symptomatic (e.g., baseline TSS ≧6) MMB or control (i.e., RUX) patients treated with the SIMPLIFY1 trial. [Diagram 44] 1 shows a graph of the TD to TI rate versus baseline platelet count subgroups at Week 24 for symptomatic (e.g., baseline TSS ≧10) MMB or control (i.e., RUX) patients treated with the SIMPLIFY1 trial. [Diagram 45] 1 shows a graph of transfusion independence (TI) response at Week 24 versus baseline platelet count subgroups for all MMB or control (i.e., RUX) patients treated in the SIMPLIFY1 trial. [Figure 46] 1 shows graphs of TI response versus baseline platelet count subgroups at Week 24 for symptomatic (e.g., baseline TSS ≧6) MMB or control (i.e., RUX) patients treated with the SIMPLIFY1 trial. [Figure 47] 1 shows graphs of TI response versus baseline platelet count subgroups at Week 24 for symptomatic (e.g., baseline TSS ≧10) MMB or control (i.e., RUX) patients treated with the SIMPLIFY1 trial. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] Momelotinib (MMB) is a potent, selective, orally bioavailable small molecule inhibitor of JAK1, JAK2, and ACVR1 developed for the treatment of myelofibrosis (MF). However, in two phase 3 clinical trials (SIMPLIFY-1 and -2), MMB did not meet the predefined secondary endpoint of TSS response in SIMPLIFY-1 and did not meet the primary endpoint of SRR in SIMPLIFY-2.

[0021] The SIMPLIFY-1 trial (NCT01969838; GS-US-352-0101) studied the efficacy and safety of MMB versus ruxolitinib (RUX) in patients with myelofibrosis who were treatment-naïve with JAK inhibitors. Patients (N=432) with high-risk or intermediate-2 or symptomatic intermediate-1 risk myelofibrosis were treated with 200 mg MMB once daily or 20 mg RUX twice daily (or as labeled) for 24 weeks, after which all patients could receive open-label momelotinib. Efficacy was measured by splenic response, total symptom score (TSS), red blood cell transfusion rate, and transfusion independence or transfusion dependence, with the goal of demonstrating non-inferiority of MMB to RUX. The primary endpoint was at least a 35% reduction in spleen volume at 24 weeks compared with baseline.

[0022] The first analysis of the results of the SIMPLIFY1 trial was reported by Mesa et al. (SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients with Myelofibrosis”, J. Clinical Oncology 2017,35(34):3844-3850). Their analysis of the SIMPLIFY-1 trial data showed that momelotinib was non-inferior to RUX for reducing spleen size in JAKi-naive patients, thus meeting the primary endpoint of the study. However, despite evidence of symptomatic benefit of momelotinib in symptomatic patients in that study, non-inferiority was not demonstrated for the secondary endpoint of total symptom score (TSS) response. MMB treatment was associated with an increased rate of transfusion independence, a decreased rate of transfusion dependence, and a decreased transfusion rate compared with RUX, all of which were nominally statistically significant.

[0023] The SIMPLIFY-2 trial (NCT02101268; GS-US-352-1214) studied the efficacy and safety of MMB versus best available treatment (BAT) in anemic or thrombocytopenic subjects with myelofibrosis previously treated with ruxolitinib (RUX). There was no lower limit for the required baseline platelet count. Efficacy, which aimed to demonstrate superiority of MMB over BAT, was measured by splenic response, total symptom score (TSS), red blood cell transfusion rate, and transfusion independence or transfusion dependence. The primary endpoint was a reduction in spleen volume of at least 35% at 24 weeks compared to baseline.

[0024] The first analysis of the results of the SIMPLIFY-2 trial was reported by Harrison et al. ("Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY2): a randomised, open-label, phase 3 trial." Lancet Haematol; Volume 5, Issue 2, February 2018, pages e73-e81). Analysis of the SIMPLIFY-2 trial data showed that momelotinib was not superior to BAT in reducing spleen size, so the trial failed to meet its primary endpoint.

[0025] In the analysis by Harrison et al., key secondary endpoints were nominally significant, but these were not considered statistically significant in the hierarchy of analytical endpoints. In general, patients in the momelotinib group had greater total symptom score (TSS) responses, fewer transfusions, greater transfusion independence, and less transfusion dependence compared with patients in the BAT group. The initial analysis was complicated by the failure to mandate discontinuation of ruxolitinib prior to the start of randomized study treatment. By not including a mandatory washout from prior ruxolitinib, assessment of splenic response was unclear for subjects in either group in this study. Furthermore, patients enrolled in this study were not selected based on splenic progression on RUX.

[0026] Reanalysis of data from the SIMPLIFY-1 and SIMPLIFY-2 trials demonstrated that momelotinib reduced thrombocytopenia in patients with thrombocytopenia of 150 × 10 per liter without momelotinib dosing causing thrombocytopenia and therefore without the need for dose reductions or interruptions due to thrombocytopenia. 9We found it to be effective in reducing spleen size (SSR), improving total symptom score (TSS), and improving transfusion independence in patients with below platelet counts. Our reanalysis indicates that MMB is effective in JAKi-naïve patients and as second-line treatment for RUX, offering the benefit of, for example, reducing splenomegaly, improving symptoms associated with myelofibrosis, and improving transfusion independence rates in a patient population with or at risk for thrombocytopenia from underlying disease and current standard of care.

[0027] Accordingly, the present disclosure describes a method of treating myeloproliferative neoplasms (MPNs), such as myelofibrosis. In some embodiments, the method comprises administering a therapeutically effective amount of momelotinib or a pharmacologic acceptable salt thereof to (i) myelofibrosis and (ii) 150×10 9 The method includes administering to a subject identified as having a platelet count of less than 1 / L.

[0028] Accordingly, the present disclosure describes a method of treating myeloproliferative neoplasms (MPNs), such as myelofibrosis, comprising administering to a subject a therapeutically effective stable dose of momelotinib, or a pharma- ceutically acceptable salt thereof, over a period of multiple weeks, wherein the subject is assessed to maintain a platelet count above a pre-determined threshold platelet count during the treatment period.

[0029] Methods for Treating Myelofibrosis In a first aspect, a method is provided for treating myeloproliferative neoplasms (MPNs), such as myelofibrosis, in subjects who do not have a significant decrease in baseline (pre-treatment) platelet count or who are not at risk of developing thrombocytopenia during treatment. In particular, a method is provided for treating MPNs in subjects who have a particularly low platelet count or who have been identified as being at risk of developing thrombocytopenia. In some embodiments, the platelet count is 150×10 9Subjects with platelet counts below 1 / L (e.g., as described herein) are targeted for treatment with the subject methods. In some embodiments, the methods provide for administration of a long-term therapeutically effective stable dose of momelotinib while avoiding the efficacy-limiting dose reductions often required for ruxolitinib patients when their platelet counts fall below a certain threshold during treatment.

[0030] As shown by the analysis of the experimental items and figures, momelotinib treatment can provide desirable therapeutic benefits to myelofibrosis patients with particularly low platelet counts compared with conventional ruxolitinib treatment. Figure 34 shows that JAKi-naïve myelofibrosis patients with 150 × 10 9 / L, e.g., 100×10 9 The results show that MMB patients in the SIMPLIFY1 study had a superior spleen response rate (SRR) compared to RUX patients when they had a baseline platelet count of less than 1 / L. The benefit of MMB over conventional RUX treatment was shown to be more pronounced when subjects were also symptomatic at the start of treatment, e.g., when subjects had a total symptom score (TSS) of 6 or greater (Figures 37, 40, 43).

[0031] In some embodiments, the method comprises administering a therapeutically effective amount of momelotinib, or a pharma- ceutical acceptable salt, to (i) a myeloproliferative neoplasm (MPN) and (ii) 150×10 9 In certain embodiments of the method, the subject is administered 100×10 9 In some embodiments, the subject is also identified as having a platelet count of at least 25×10 9 / L, e.g., at least 30 × 10 9 / L, at least 40 × 10 9 / L, or at least 50 × 10 9 / L. In some embodiments, the subject is identified as having a platelet count of 25×10 9 / L or more and 50×10 9 In some embodiments, the subject is identified as having a platelet count of less than 50×10 9 / L or more and 100×109 In some embodiments, the subject is identified as having a platelet count of less than 100×10 9 / L or more and 150 x 10 9 Platelet counts of less than 150 × 10 9 / L ~ approx. 450×10 9 A platelet count of 150 × 10 / L is considered to be at normal levels. Thrombocytopenia is generally defined as a platelet count above 150 × 10 9 Platelet counts below 50 × 10 / L and are further characterized by grades 1–4 depending on the subject's specific platelet count. In some cases, grades 3 or 4 (50 × 10 9 Thrombocytopenia (platelet counts less than 10 / L) is considered severe and requires urgent treatment.

[0032] The subject's platelet count can be determined before the initiation of momelotinib treatment. Thus, aspects of the method include determining platelet levels (e.g., platelet count) in a patient sample. The platelet count can be a baseline platelet count. In some embodiments, the baseline platelet count is determined within 1 week before the initiation of momelotinib treatment, where the patient i) has not been treated with a previous JAK inhibitor therapy for at least 2 weeks before the initiation of momelotinib treatment, or ii) has been naive to a previous JAKi therapy. In some embodiments, the baseline platelet count is determined from a sample taken within 2 or 3 weeks before the initiation of momelotinib treatment, where the patient has not been treated with a previous JAK inhibitor therapy for at least 2 weeks before the platelet sample is taken. In certain embodiments, the patient's platelet count is monitored during treatment, for example, to determine whether any significant change from baseline occurs (e.g., a decrease in platelet count from baseline of 25% or less, e.g., 20% or less, 15% or less, 10% or less, or 5% or less). Any convenient method can be utilized to determine the patient's platelet count, for example, by sampling. Methods for counting platelets that can be adapted for use in the methods disclosed herein include, but are not limited to, electronic particle counting methods (e.g., Coulter S-plus), optical counting methods (e.g., Ortho ELT8), and counting methods using a hemocytometer.

[0033] Figures 31-33 show plots of the mean platelet counts of subjects for MMB vs. RUX in the SIMPLIFY1 study. The data show that subjects treated with MMB were able to maintain platelet levels during the treatment period, e.g., during the 24-week double-blind study period. In comparison, RUX subjects showed a significant decrease in platelet counts from baseline, which can often lead to a required dose reduction (e.g., as described herein). Thus, MMB subjects were at lower risk of developing thrombocytopenia (e.g., grade 3 or 4 thrombocytopenia) or having to reduce undesirable doses, since the subjects were able to mostly maintain their platelet counts during treatment. In comparison, dose reductions (e.g., as described herein) may be required during conventional RUX treatment to avoid or address the occurrence of adverse events such as thrombocytopenia.

[0034] Thus, aspects of the present disclosure include methods of treating MPN subjects using MMB (e.g., as described herein) without causing thrombocytopenia, increased risk of thrombocytopenia, or worsening of the degree of thrombocytopenia (e.g., caused by a decrease in platelet count during treatment) and without requiring dose reduction or interruption due to thrombocytopenia during the treatment period. In some embodiments, the method includes administering a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof over a multi-week treatment period, i.e., administering MMB or a pharmaceutically acceptable salt thereof without dose reduction. Subjects treated according to these methods can maintain a platelet count above a predetermined threshold platelet count during the treatment period. In certain embodiments, the MPN is MF.

[0035] A "stable dose" is an amount of drug administered during a set time unit (e.g., one day up to one week) according to a dosing regimen (e.g., as described herein) that continues for multiple regular dosing intervals without dose reduction (i.e., at a constant dose), thereby maintaining a therapeutically effective level of the drug in the subject during the treatment period. In certain embodiments, the stable dose is a consistent daily dose (e.g., once a day) that is maintained during the treatment period. In some embodiments, the amount of drug administered remains constant, although the specific dosing regimen may be adjusted. In some embodiments, the stable dose is administered once or twice a day according to a specific regimen. Any convenient therapeutically effective dose of momelotinib (e.g., as described herein) can be selected as the stable dose for use in the subject method. The stable dose can be administered according to any convenient regimen (e.g., as described herein). In certain embodiments, the therapeutically effective stable dose of momelotinib or a pharma- ceutically acceptable salt thereof is 200 mg / day. In certain embodiments, the stable dose is administered once a day. In certain embodiments, the stable dose is BID. In certain embodiments, the stable dose is administered orally.

[0036] As summarized above, subjects treated according to these methods can maintain a platelet count above a predetermined threshold platelet count during the treatment period. Thus, embodiments of the methods disclosed herein include administering MMB to a subject assessed to maintain a platelet count above a predetermined threshold platelet count during the treatment period. The predetermined threshold platelet count can be a platelet count level determined based on the subject's platelet count before treatment begins. In some embodiments, the subject's platelet count before treatment begins is referred to as a baseline platelet count (e.g., as described herein). In some embodiments, the predetermined threshold platelet count is a platelet level that is up to 25% below the subject's baseline platelet count, e.g., within 20%, within 15%, within 10%, or within 5% below the subject's baseline platelet count. In some embodiments, the predetermined threshold platelet count is selected to be at a level of 75% or more of the baseline platelet count, e.g., 80% or more, 85% or more, 90% or more, or 95% or more of the baseline platelet count.

[0037] Typically, the baseline platelet count is determined within one week prior to initiation of MMB therapy, and the patient has not been treated with a previous JAK inhibitor therapy for at least two weeks prior to initiation of MMB therapy. Prior JAK inhibitor therapy, such as RUX therapy, can affect the platelet count of a treated subject and thus skew the subject's expected platelet count in the absence of therapy.

[0038] The treatment period during which the therapeutically effective stable dose is administered can be long term. In some embodiments, the multiple weeks without dose reduction are 8 weeks or more, for example 10 weeks or more. In some embodiments, the multiple weeks without dose reduction are 12 weeks or more. In some embodiments, the multiple weeks without dose reduction are 24 weeks or more (for example more than 24 weeks), for example 28 weeks or more, 32 weeks or more, 36 weeks or more, 40 weeks or more, 44 weeks or more, 48 weeks or more, 52 weeks or more, or more. In some embodiments, the treatment period without dose reduction is 1 year or more, for example 2 years or more, 3 years or more, 4 years or more, 5 years or more, 6 years or more, 7 years or more, or 8 years or more.

[0039] In some embodiments, the subject receives 50×10 9 / L or more, e.g., 100×10 9 / L or more, 150×10 9 / L or more, 200×10 9 / L or more, 250×10 9 / L or more, 300×10 9 / L or greater. In some embodiments, subjects receive 150×10 9 In some embodiments, subjects maintain a platelet count above a threshold platelet count of less than 50×10 / L during the treatment period. 9 / L or more and 150 x 10 9 In some embodiments, the threshold platelet count is less than 25×10 9 / L or more and 50×10 9 / L. In some embodiments, the threshold platelet count is less than 50×10 9 / L or more and 100×10 9 / L. In some embodiments, the threshold platelet count is less than 100×10 9 / L or more and 150 x 10 9 / L.

[0040] In some embodiments, the subject is a subject identified or diagnosed as having or at risk of having myeloproliferative neoplasms (MPNs). "Myeloproliferative diseases" and "myeloproliferative neoplasms (MPNs)", particularly polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are a diverse but interrelated group of clonal disorders of multipotent hematopoietic stem cells that share a wide range of biological, pathological, and clinical features, including relative overproduction of one or more cells from bone marrow, growth factor-independent colony formation in vitro, myeloid cell hyperplasia, extramedullary hematopoiesis, spleen and hepatomegaly, and thrombotic and / or hemorrhagic diathesis. The International Working Group for the Study and Treatment of Myeloproliferative Neoplasms (IWG-MRT) has been established to describe and define these conditions (see, for example, Vannucchi et al., CA Cancer J.Clin., 2009, 59:171-191).

[0041] Any convenient method can be used to identify or diagnose the subject that is a candidate for treatment according to the subject method. Subjects, particularly human patients, with MPN, particularly MF (e.g. PMF), can be identified using methods such as the IWG-MRT criteria described above. Some MPNs are associated with dysregulation of JAK1 and JAK2 signaling. Subjects that are "at risk" of a particular form of MPN are subjects that have an early stage form of the disease, and can include, for example, subjects that have the genetic markers thereof, such as the JAK2V617F allele associated with PV (>95%), ET (60%), and PMF (60%). Subjects are also considered to be "at risk" of a form of MPN if they already show symptoms of an early stage form.

[0042] In certain embodiments, the MPN diagnosed in the subject is myelofibrosis (MF). Myelofibrosis is meant to include primary myelofibrosis (PMF), post-polycythemia vera MF (post-PV MF) and post-essential thrombocythemia MF (post-ET MF). The diagnosis of PMF can be made according to the World Health Organization (WHO) 2016 criteria. The diagnosis of post-PV / ET MF can be confirmed according to the International Working Group-Research and Treatment of Myeloproliferative Neoplasms (IWG-MRT) criteria.

[0043] In some cases, the subject is classified as having intermediate or high risk MF. Subjects with myelofibrosis can be classified as having low risk, intermediate-1 risk, intermediate-2 risk, or high risk short survival, with median survival of about 11, 8, 4, and 2 years, respectively. Subjects can be classified according to the criteria summarized in Table 1. See, for example, Cervantes et al. ("New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment." Blood. 2009;113:2895-2901).Risk stratification of patients with MF has also been performed using the International Prognostic Scoring System (IPSS) (see Cervantes et al.), dynamic IPSS (DIPSS) (see Passamonti et al. “A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)” Blood 2010;115:1703-1708), DIPSS plus (Gangat et al. “DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status”, J. Clin. Oncol.,2011;29:392-397), and mutation-enhanced IPSS (MIPSS) (Vannucchi et al., “Mutation-enhanced International This can be achieved by following the “MIPSS Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM&IWG-MRT project [abstract]”, Blood. 2014;124:405. [Table 1] NR: Not reached, a Risk factors include age >65 years, constitutional symptoms (defined as weight loss >10% of baseline in the year prior to diagnosis, and / or unexplained fever or excessive sweating lasting >1 month), hemoglobin >2510 9 / L, with 1% peripheral blood blasts.b Risk factors (scores) included age >65 years (1), constitutional symptoms (1), hemoglobin <10 g / dL (2), and white blood cell count >2510. 9 / L(1), and peripheral blood blasts 1%. c Scoring was based on the DIPSS risk classification (low risk, 0 points; intermediate-1 risk, 1 point; intermediate-2 risk, 2 points; high risk, 3 points), and on additional risk factors (unfavorable karyotype, 1 point; platelet count <100 10 9 / L, 1 point; need for transfusion, 1 point). d Risk factors (scores) included age >60 years (1.5), constitutional symptoms (0.5), hemoglobin <100 g / L (0.5), and platelet count <20010 9 / L (1.0), triple-negative mutation status (1.5), JAK2 or MPL mutation (0.5), ASXL1 (0.5), and SRSF2 (0.5).

[0044] In certain embodiments, the patient targeted for treatment by the subject method is identified as having myelofibrosis and being symptomatic. A symptomatic patient is one who is exhibiting one or more symptoms of the disease. A symptomatic patient can be assessed using the Myeloproliferative Neoplasms-Symptom Assessment Form (MPN-SAF) Total Symptom Score (TSS) guidelines. See, for example, Gwaltney C, Paty J, Kwitkowski VE et al. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leukemia Research. 2017. In some embodiments, a symptomatic myelofibrosis patient is one who is identified as having a Total Symptom Score (TSS) of 6 or more, for example, 7 or more, 8 or more, 9 or more, or 10 or more.

[0045] The subject method can be utilized as a first-line treatment of the MPN of interest. In some cases, the MPN is myelofibrosis. The patient treated according to the method of the present disclosure may be naive to Janus kinase inhibitor (JAKi) treatment. Second-line treatment methods are also provided. In certain embodiments, the patient treated according to the method of the present disclosure has been previously treated with a JAK inhibitor. In certain embodiments, the JAK inhibitor is ruxolitinib (RUX). In certain embodiments, the JAK inhibitor is fedratinib. In certain cases, the previously treated patient responded inadequately to or did not benefit sufficiently from, or was intolerant to, a Janus kinase inhibitor, such as RUX or fedratinib. In some embodiments, patients who have not responded or become non-responsive to previous treatments (e.g., with RUX or fedratinib) are treated according to the method of the present disclosure. In some cases, the subject has not obtained beneficial or desired clinical results from the previous treatment, as determined, for example, by a primary or secondary endpoint.

[0046] In certain embodiments, the subject or patient is (i) disease treatment-naïve (i.e., naïve), (ii) has received and is intolerant to a previous treatment (e.g., a JAKi such as RUX or fedratinib), or (iii) has not fully benefited from, has not responded to, is resistant to, or relapses to a previous treatment (e.g., a JAKi such as RUX). In certain embodiments, the patient does not fully benefit from a previous treatment (e.g., a JAKi such as RUX or fedratinib) because a reduction in the required dose (e.g., due to adverse events) results in less therapeutic effect.

[0047] "Treatment" or "treating" is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting a disease or condition (e.g., reducing one or more symptoms or signs attributable to a disease or condition and / or reducing the severity of the disease or condition); b) delaying or arresting the onset of one or more clinical symptoms associated with a disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and / or preventing or delaying the spread (e.g., metastasis) of the disease or condition; c) relieving the disease, i.e., causing regression of clinical symptoms (e.g., improving the disease state, alleviating or ameliorating one or more symptoms or signs, providing partial or complete remission of the disease or condition, enhancing the effect of another drug therapy, slowing the progression of the disease, improving quality of life, and / or prolonging survival; and / or d) improving or stabilizing or preventing the reduction of one or more clinical endpoints (e.g., as described herein), including, but not limited to, transfusion independence, conversion from fluid dependence to independence, total symptom score (TSS), spleen response (SRR), and improvement of anemia.

[0048] As a chronic disease, MF is characterized by high disease burden, disease complications, reduced quality of life (QoL), and short survival. Patients suffering from the disease experience a variety of symptoms that negatively affect social functioning, physical activity, independence in daily activities, and overall productivity. The most common symptoms affecting patients with MF include systemic symptoms related to systemic inflammation, such as night sweats, fever, weight loss, abdominal symptoms secondary to splenomegaly, such as abdominal discomfort / pain, early satiety, dyspnea, and diarrhea, symptoms of anemia, such as fatigue, and symptoms secondary to complications of MF. Fatigue (tiredness, tiredness) has been identified as the most common and most severe symptom.

[0049] The embodiments of the present disclosure include a method for at least improving one or more symptoms or signs of disease of a subject identified as having MPN.In some cases, the MPN is myelofibrosis, and one or more symptoms of myelofibrosis are as described herein.The symptoms of myelofibrosis that can be improved include, but are not limited to, fatigue, night sweats, fever, cachexia, bone pain, pruritus, weight loss, abdominal distension and pain, early satiety, dyspnea, and diarrhea.Other signs of disease include, but are not limited to, anemia, thrombocytopenia, and hepatosplenomegaly.

[0050] Of particular interest is ongoing disease treatment, where the treatment stabilizes or alleviates the patient's undesirable clinical symptoms.Expected progression-free survival can be measured in months to years, depending on prognostic factors, including recurrence, stage, and other factors.Extended survival includes, but is not limited to, at least 1 month, about 2 months, about 3 months, about 4 months, about 6 months, about 1 year, about 2 years, about at least 3 years or more.

[0051] Overall survival time can also be measured in months to years. The patient's symptoms may remain static or be alleviated. The term "effective amount" refers to an amount that, when administered to a subject for treating a disease, can be effective to induce a desired biological or medical response, including an amount of a compound that is sufficient to perform such treatment for the disease. The effective amount varies depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated. The effective amount can include a variety of amounts.

[0052] The terms "subject" and "patient" are used interchangeably and refer to an animal, such as a mammal (including a human), that has been or will be the subject of treatment, observation, or experiment. The methods described herein may be useful in human therapy and / or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human. The methods of the present disclosure can be used to treat a variety of other mammals. For example, mammals can be treated, including but not limited to cows, sheep, goats, horses, dogs, cats, guinea pigs, rats, or other bovine, ovine, equine, canine, feline, rodent, or murine species.

[0053] "Human in need thereof" refers to a human having or suspected of having a disease or condition that would benefit from a particular treatment, e.g., treatment with a compound according to the present application. The term "subject in need thereof" or "patient in need thereof" refers to a subject or patient having, diagnosed as having, or suspected of having, a disease, disorder, or condition that would benefit from the treatments described herein.

[0054] The term "therapeutically effective amount" of a compound or a pharma- ceutically acceptable salt, isomer, prodrug, or solvate thereof means an amount sufficient to provide a therapeutic benefit, such as treating, for example, relieving one or more symptoms, or slowing the progression of a disease, when administered to a subject. The therapeutically effective amount may vary depending on the subject and the disease or condition being treated, the subject's weight and age, the severity of the disease or condition, and the method of administration, and these can be readily determined.

[0055] The compounds of the present application or compositions thereof may be administered once, twice, three times, or four times a day using any suitable mode described herein. Also, administration or treatment with MMB may continue for several days. For example, treatment usually continues for at least 7 days, 14 days, or 28 days for one cycle of treatment. Treatment cycles are generally known and often alternate with rest periods of about 1 to 28 days, usually about 7 days or about 14 days, between cycles. In other embodiments, treatment cycles may also be continuous.

[0056] In treating the identified subject, a suitable unit dose of the MMB compound is generally about 0.01-500 mg per kg of patient body weight per day, which can be administered in single or multiple doses. Dosage levels are about 0.1 to about 250 mg / kg per day, for example, about 0.5 to about 100 mg / kg per day. Suitable dosage levels may be about 0.01-250 mg / kg / day, about 0.05-100 mg / kg / day, or about 0.1-50 mg / kg / day. Within this range, dosages may be 0.05-0.5, 0.5-5, or 5-50 mg / kg per day. Suitable unit doses are typically in the range of 10-500 mg, for example, 50-400 mg, for example, 100, 150, 200, 250, or 300 mg. For oral administration, the composition is preferably provided in the form of a tablet containing 1.0 to 1000 milligrams of active ingredient, in particular 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of active ingredient. The dosage may be selected, for example, to any dose within any of these ranges for therapeutic effect and / or symptomatic adjustment of the dosage to the patient being treated. The compound is preferably administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

[0057] It will be understood that the specific dose level and frequency of administration in any particular patient may vary and will depend on a variety of factors, including the activity of the particular compound used, the metabolic stability and length of action of that compound, age, body weight, general health, sex, diet, mode and time of administration, excretion rate, drug combination, the severity of the particular condition, and the host being treated.

[0058] In some embodiments of the subject method, the therapeutically effective amount of the MMB compound described herein is a dose of 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, or 300 mg. In certain cases, the therapeutically effective amount is 100 mg / day to 300 mg / day, e.g., 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, or 300 mg / day. In certain cases, the therapeutically effective amount is 50 mg / day to 200 mg / day, e.g., 50 mg / day, 100 mg / day, 150 mg / day, or 200 mg / day. In some embodiments of the subject method, the therapeutically effective amount is 200 mg / day. Administration can be oral. In some cases, administration is once daily. In some cases, administration is BID, e.g., in equally divided doses. In some cases, MMB is administered with food. In some cases, MMB is administered without food.

[0059] For patients unable to take tablets orally, a therapeutically effective amount of the MMB compound can be administered by another route, for example, via a nasogastric tube.

[0060] The improved results of MMB therapy resulting from carrying out the subject method may be manifested as an improvement in one or more clinical endpoints (e.g., as described herein), such as anemia response, splenic response, and / or symptom response. By "anemic response" is meant an increase in the patient's hemoglobin level, or a patient who was transfusion dependent becomes transfusion independent. Desirably, a minimal increase in hemoglobin of 0.5 g / dL, e.g., 1.0 g / dL, 1.5 g / dL, or 2.0 g / dL, lasting for a minimum of 8 weeks is achieved, which is the level of improvement specified by the International Working Group (IWG) consensus criteria. However, a small but medically significant increase in hemoglobin is also considered to be within the scope of the term "anemic response." "Transfusion independence" refers to a subject who is an anemia endpoint and does not require RBC transfusions for 12 weeks and has a hemoglobin level below 8 g / dL to 8.5 g / dL for 12 weeks. In some embodiments, the 12 week period of transfusion independence is the final 12 weeks of a 24 week study period. The rate of red blood cell (RBC) transfusion independence at week 24 of the study means the proportion of subjects who were transfusion independent at week 24, except in cases associated with clinically significant overt bleeding.

[0061] "Splenic response" refers to a reduction in the size of a patient's spleen, as assessed either by palpation of a previously palpable spleen during a physical exam or by imaging. The IWG consensus criteria are either a minimum 50% reduction in splenomegaly (enlarged spleen) of at least 10 cm at baseline (pre-treatment) or a palpable splenomegaly of the spleen palpable more than 5 cm below the left costal margin at baseline that is no longer palpable. However, smaller reductions are also considered to be within the scope of the term "splenic response." Splenic enlargement can be assessed by palpation. Splenic size and volume can also be measured by imaging modalities such as ultrasound, CT, and MRI. In some cases, a normal splenic size is considered to be approximately 11.0 cm craniocaudal length.

[0062] By "symptomatic response" or "symptomatic response" is meant at least a 50% reduction in a patient's average daily TSS compared to a baseline TSS determined at or before the start of treatment (e.g., as described herein).

[0063] Momelotinib In the methods described herein, momelotinib, or a pharma- ceutically acceptable salt thereof, is administered in a therapeutically effective amount.

[0064] Momelotinib (MMB), an inhibitor of JAK (JAK1 and JAK2) and ACVR1, is also known as N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide or CYT-0387, and has the structure of Formula I: [ka]

[0065] "Pharmaceutically acceptable salt" refers to a salt of a compound that retains the biological effectiveness and properties of the underlying compound and is not biologically or otherwise undesirable. MMB can exist as an acid addition salt. Pharmaceutically acceptable acid addition salts of basic drugs may be prepared using inorganic and organic acids. Acids useful for reacting with MMB to form pharma-ceutically acceptable salts (acid addition salts), and methods for achieving the same, are known to those skilled in the art. When MMB exists as an acid addition salt, MMB free base can be obtained by basifying a solution of the acid salt. Solvates are formed by the interaction of a solvent with the MMB compound. Solvates of the salts of the MMB compounds described herein are also used in certain embodiments of the methods described herein. In some cases, the solvates of the MMB compounds are hydrates.

[0066] The method embodiments disclosed herein use any convenient pharma- ceutically acceptable acid addition salt of momelotinib, or a solvate or hydrate thereof. In some embodiments, the momelotinib compound is a hydrochloride salt. In certain embodiments, the compound hydrochloride salt found in the subject method is momelotinib monohydrochloride salt of formula II: [ka]

[0067] In certain embodiments, momelotinib monohydrochloride is an anhydrate. In certain embodiments, momelotinib monohydrochloride is a hydrate, e.g., a monohydrate.

[0068] In certain embodiments, the momelotinib hydrochloride used is momelotinib dihydrochloride of formula III: [ka]

[0069] In certain embodiments, momelotinib dihydrochloride is an anhydrate. In certain embodiments, momelotinib dihydrochloride is a hydrate, e.g., momelotinib dihydrochloride monohydrate.

[0070] Embodiments of the methods described herein use any crystalline salt form of momelotinib, including but not limited to those forms described in WO20 / 15191846, the disclosure of which is incorporated herein by reference. In some embodiments, crystalline salt forms of momelotinib are referred to as polymorphic forms of the compound.

[0071] In some embodiments, the MMB compound used is momelotinib dihydrochloride monohydrate in crystalline form II. Crystalline form II is characterized by one or more parameters as follows: Crystalline form II can be characterized by unit cell parameters a=10.2837(6)A, b=10.4981(6)A, c=11.5143(7)A, a=83.297(2)°, β=87.649(2)°, γ=67.445(2)° at T=100°K, and a triclinic P1 space group. Crystalline form II can be characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG. 19. Crystalline Form II can be characterized by an X-ray powder diffraction (XRPD) pattern with peaks at 7.7°, 19.3°, 24.0°, 25.7°, and 29.6°2-Θ+0.2°2-Θ. Crystalline Form II can be characterized by a differential scanning calorimetry (DSC) pattern substantially as shown in Figure 22. Crystalline Form II can be characterized by a dynamic vapor sorption (DVS) pattern substantially as shown in Figure 28, or by a thermogravimetric analysis (TGA) pattern substantially as shown in Figure 25.

[0072] In some embodiments, the MMB compound used is anhydrous momelotinib monohydrochloride anhydrate in crystalline form I. Crystalline form I is characterized by one or more parameters as follows: Crystalline form I can be characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG. 20. Crystalline form I can be characterized by an X-ray powder diffraction ("XRPD") pattern with peaks at 13.5°, 20.9°, 26.1°, 26.6°, and 28.3°2-Θ+0.2°2-Θ. Crystalline form I can be characterized by a differential scanning calorimetry (DSC) pattern substantially as shown in FIG. 23. Crystalline form I can be characterized by a TGA substantially as shown in FIG. 26.

[0073] In some embodiments, the MMB compound used is momelotinib monohydrochloride anhydrate, which is crystalline form III. Crystalline form III is characterized by one or more parameters such as: Crystalline form III can be characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG. 21. Crystalline form III can be characterized by an X-ray powder diffraction pattern with peaks at 12.7°, 14.6°, 17.8°, 19.7°, and 23.3°2-Θ+0.2°2-Θ. Crystalline form III can be characterized by a differential scanning calorimetry (DSC) pattern substantially as shown in FIG. 24. Crystalline form III can be characterized by a TGA substantially as shown in FIG. 27.

[0074] In some embodiments, the MMB compound used is momelotinib dihydrochloride anhydrate form IV (MMB form IV). Crystalline form IV is characterized by one or more parameters as follows: Crystalline form III can have an XRPD pattern with peaks at 5.5°, 10.1°, 14.9°, 25.1°, and 26.6°2-Θ+0.2°2-Θ. [Table 2]

[0075] The following patent applications are incorporated by reference for all purposes, including but not limited to the use of MMBs described therein: International Application No. PCT / AU2008 / 000339, filed March 12, 2008, and International Application No. PCT / AU2011 / 001551, filed November 29, 2011, and International Application No. PCT / US2015 / 035316, filed June 11, 2015, and International Application No. PCT / US2017 / 045957, filed August 8, 2017.

[0076] Pharmaceutical Compositions MMB compounds are usually administered in the form of a pharmaceutical composition. The method embodiments disclosed herein include administering a pharmaceutical composition comprising an MMB compound disclosed herein, or a pharma- ceutically acceptable salt thereof, or a solvate or hydrate thereof, and one or more pharma- ceutically acceptable vehicles selected from carriers, adjuvants, and excipients.

[0077] The pharmaceutical composition may be administered in a single dose or multiple doses. The pharmaceutical composition may be administered by various methods. In certain embodiments, the pharmaceutical composition is administered by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

[0078] Oral administration is the presently preferred route of administration of the MMB compounds described herein. In a presently preferred embodiment, the MMB forms or compositions described herein are formulated for oral administration using a pharma- ceutically acceptable carrier. The pharmaceutical compositions formulated for oral administration may be in the form of tablets, capsules, cachets, dragees, lozenges, liquids, gels, syrups, slurries, elixirs, suspensions, or powders.

[0079] Administration may be, for example, via capsules or enteric coated tablets. In preparing pharmaceutical compositions containing the MMB compounds described herein, or pharma- ceutically acceptable salts or solvates or hydrates thereof, the active ingredient is usually diluted with an excipient and / or enclosed within such a carrier, which may be in the form of a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it may be in the form of a solid, semi-solid, or liquid material that serves as a vehicle, carrier, or medium for the active ingredient. Thus, the composition may be in the form of tablets, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders, for example, containing up to 10% by weight of the active compound.

[0080] To prepare solid compositions such as tablets, the primary active ingredient may be mixed with pharmaceutical excipients to form a solid preformulation composition containing a homogenous mixture of any of the compounds of the above formulas or a pharma- ceutically acceptable salt, prodrug, or solvate thereof. When these preformulation compositions are referred to as homogenous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets and capsules. Tablets of the MMB compounds described herein may be coated or otherwise compounded to provide a dosage form that confers the advantage of prolonged action or to protect against the acidic conditions of the stomach. For example, a tablet or pill may include an inner dosage and an outer dosage component, the latter being in an encapsulated form over the former. The two components may be separated by an enteric layer that serves to resist disintegration in the stomach and allow the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials may be used for such enteric layers or coatings, including a number of polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

[0081] The particular dose level of the MMB compounds described herein for a particular subject will depend on a variety of factors, including the activity of the particular compound used, age, body weight, general health, sex, diet, time of administration, route of administration, as well as the excretion rate in the subject being treated, the drug combination, and the severity of the particular disease. For example, the dose may be expressed as milligrams of MMB compound per kilogram of subject body weight (mg / kg). Doses of about 0.01 to 200 mg / kg may be appropriate. In some embodiments, between about 0.01 and 150 mg / kg may be appropriate. In other embodiments, doses of 0.05 to 100 mg / kg may be appropriate. Normalizing according to subject body weight is particularly useful when adjusting dosages between subjects of widely differing sizes, for example, when using drugs in both children and adults, or when translating effective dosages in non-human subjects, such as dogs, to dosages suitable for human subjects.

[0082] Pharmaceutically acceptable vehicle Pharmaceutically acceptable vehicles include carriers, adjuvants, and excipients, such as inert solid diluents and fillers, diluents including sterile aqueous solutions and various organic solvents, permeation enhancers, solubilizing agents, and auxiliary agents.

[0083] The term "carrier" refers to diluents or fillers, disintegrants, precipitation retardants, surfactants, glidants, binders, lubricants, antioxidants, and other excipients and vehicles administered with the MMB compound. Examples of carriers useful in dosage forms administered in the methods described herein include, but are not limited to, aluminum monostearate, aluminum stearate, carboxymethylcellulose, sodium carboxymethylcellulose, crospovidone, glyceryl isostearate, glyceryl monostearate, hydroxyethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, hydroxyoctacosanyl hydroxystearate, hydroxypropylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, lactose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 188, poloxamer 237, poloxamer 407, povidone, silicon dioxide, colloidal silicon dioxide, silicone, silicone adhesive 4102, and silicone emulsion. However, it is to be understood that the carriers selected for the pharmaceutical compositions provided in this disclosure, and the amounts of such carriers in the compositions, may vary depending on the formulation method (e.g., dry granulation formulation, solid dispersion formulation).

[0084] The term "diluent" or "bulking agent" generally refers to a substance used to dilute the MMB compound before delivery. Diluents may also function to stabilize the compound. Examples of diluents may include starch, sugars, disaccharides, sucrose, lactose, polysaccharides, cellulose, cellulose ethers, hydroxypropyl cellulose, sugar alcohols, xylitol, sorbitol, maltitol, microcrystalline cellulose, calcium or sodium carbonate, lactose, lactose monohydrate, dicalcium phosphate, cellulose, compressible sugar, dibasic calcium phosphate dihydrate, mannitol, microcrystalline cellulose, and tribasic calcium phosphate.

[0085] The term "disintegrant" generally refers to a substance that, when added to a solid preparation, promotes its disintegration or breakup after administration, allowing the release of the active ingredient as efficiently as possible, and allows its rapid dissolution. Examples of disintegrants include corn starch, sodium starch glycolate, croscarmellose sodium, crospovidone, microcrystalline cellulose, modified corn starch, sodium carboxymethyl starch, povidone, pregelatinized starch, and alginic acid.

[0086] The term "sedimentation retardant" generally refers to a substance that prevents or retards the precipitation of an active agent. One example of a sedimentation retardant is hydroxypropyl methylcellulose.

[0087] The term "surfactant" generally refers to a compound that reduces the surface tension between two liquids or between a liquid and a solid. Examples of surfactants include poloxamer and sodium lauryl sulfate.

[0088] The term "glidant" generally refers to a substance used in tablet and capsule formulations to improve flow characteristics during tablet compression and to create an anti-caking effect. Examples of glidants include colloidal silicon dioxide, talc, fumed silica, starch, starch derivatives, and bentonite.

[0089] The term "binder" generally refers to any pharma- ceutically acceptable film that can be used to bind the active and inactive components of the carrier together to keep them coherent and separate. Examples of binders include hydroxypropyl cellulose, hydroxypropyl methylcellulose, povidone, copovidone, ethyl cellulose, gelatin, and polyethylene glycol.

[0090] The term "lubricant" generally refers to a substance added to a powder blend to prevent the compressed powder mass from sticking to the equipment during the tableting or encapsulation process. Lubricants can aid in the ejection of the tablet from the die during tableting and improve powder flow. Examples of lubricants include magnesium stearate, stearic acid, silica, fats, calcium stearate, polyethylene glycol, sodium stearyl fumarate, or talc, and solubilizers such as lauric acid, oleic acid, and fatty acids, including Cg / Cio fatty acids.

[0091] The term "antioxidant" generally refers to a substance that inhibits the oxidation of other substances. In certain embodiments of the present invention, an antioxidant is added to the pharmaceutical composition. Examples of antioxidants include ethylenediaminetetraacetic acid, ethylenediaminetetraacetic acid disodium salt, sodium sulfite, sodium metabisulfite, sodium bisulfite, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ascorbic acid, ascorbyl palmitate, thioglycerol, thioglycolic acid, tocopherol (vitamin E), D-alpha tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS), and propyl gallate. In certain embodiments, the antioxidant is propyl gallate.

[0092] In some embodiments, the pharmaceutical composition comprises MMB dihydrochloride monohydrate Form II and an antioxidant selected from butylated hydroxyanisole (BHA), ascorbic acid, and propyl gallate. In certain embodiments, the pharmaceutical composition comprises MMB dihydrochloride monohydrate Form II and an antioxidant, propyl gallate. The antioxidant may be present in an amount sufficient to prevent, inhibit, and / or reduce degradation of the MMB active ingredient (such as MMB Form II). By way of example, the antioxidant may be present in the pharmaceutical composition in an amount of about 0.001, about 0.002%, about 0.005%, about 0.01%, about 0.02%, about 0.05%, about 0.1%, about 0.2%, about 0.5%, or about 1% by weight. In one embodiment, the pharmaceutical composition comprises propyl gallate in an amount of about 0.001%, about 0.01%, about 0.1%, about 0.2%, about 0.5%, or about 1%. In certain embodiments, the pharmaceutical composition comprises MMB dihydrochloride monohydrate Form II and about 0.2% propyl gallate.

[0093] In certain embodiments, the pharmaceutical crude comprises a pharmaceutical composition comprising an MMB compound active agent (e.g., MMB dihydrochloride monohydrate Form II) and one or more of (a)-(e): a) at least one diluent; b) at least one disintegrant, c) at least one glidant, d) at least one lubricant, and e) at least one antioxidant.

[0094] In some embodiments, the pharmaceutical composition comprises at least one or at least two diluents. In certain embodiments, the pharmaceutical composition comprises one or two diluents. In certain embodiments, the diluent is selected from mannitol, microcrystalline cellulose, lactose, dextrose, sucrose, ludiflash, F-melt, advantose, GalenlQ, and any mixture thereof. In one embodiment, the diluent is mannitol, microcrystalline cellulose, or a mixture thereof.

[0095] In some embodiments, the pharmaceutical composition comprises at least one disintegrant. In certain embodiments, the pharmaceutical composition comprises one disintegrant. In certain embodiments, the disintegrant is sodium starch glycolate. In one embodiment, the disintegrant is croscarmellose sodium. In another embodiment, the disintegrant is crospovidone.

[0096] In some embodiments, the pharmaceutical composition comprises at least one glidant. In certain embodiments, the pharmaceutical composition comprises one glidant. In one embodiment, the glidant is colloidal silicon dioxide.

[0097] In some embodiments, the pharmaceutical composition comprises at least one lubricant. In certain embodiments, the pharmaceutical composition comprises one lubricant. In one embodiment, the lubricant is magnesium stearate.

[0098] In a particular embodiment, the pharmaceutical composition comprises MMB dihydrochloride monohydrate Form II, at least one diluent, at least one disintegrant, at least one glidant, at least one lubricant, and at least one antioxidant.In a further embodiment, the at least one diluent is microcrystalline cellulose, the at least one disintegrant is sodium starch glycolate, the at least one glidant is colloidal silicon dioxide, the at least one lubricant is magnesium stearate, and the at least one antioxidant is propyl gallate.In yet another embodiment, the at least one diluent is lactose, the at least one disintegrant is sodium starch glycolate, the at least one glidant is colloidal silicon dioxide, the at least one lubricant is magnesium stearate, and the at least one antioxidant is propyl gallate.

[0099] In another embodiment, the pharmaceutical composition comprises MMB dihydrochloride monohydrate Form II, at least two diluents, at least one disintegrant, at least one glidant, at least one lubricant, and at least one antioxidant. In yet another embodiment, the at least two diluents are microcrystalline cellulose and lactose, the at least one disintegrant is sodium starch glycolate, the at least one glidant is colloidal silicon dioxide, the at least one lubricant is magnesium stearate, and the at least one antioxidant is propyl gallate.

[0100] In certain embodiments, the pharmaceutical composition comprises an MMB compound that is at least about 80% MMB dihydrochloride monohydrate Form II. In further embodiments, the pharmaceutical composition comprises an MMB compound that is at least about 85% MMB dihydrochloride monohydrate Form II. In yet another embodiment, the pharmaceutical composition comprises an MMB compound that is at least about 90% MMB dihydrochloride monohydrate Form II. In yet another embodiment, the pharmaceutical composition comprises an MMB compound that is at least about 95% MMB dihydrochloride monohydrate Form II. In certain embodiments, the pharmaceutical composition comprises an MMB compound that is at least about 97% MMB dihydrochloride monohydrate Form II. In other embodiments, the pharmaceutical composition comprises an MMB compound that is at least about 98% MMB dihydrochloride monohydrate Form II. In yet other embodiments, the pharmaceutical composition comprises an MMB compound that is at least about 99% MMB dihydrochloride monohydrate Form II. In yet other embodiments, the pharmaceutical composition comprises an MMB compound that is at least about 99.5% MMB dihydrochloride monohydrate Form II. In certain embodiments, the pharmaceutical composition comprises an MMB compound that is at least about 99.9% MMB dihydrochloride monohydrate Form II.

[0101] It is to be understood that the pharmaceutical compositions include the pharma- ceutically acceptable carriers detailed herein, just as if each and every combination of pharma- ceutically acceptable carriers were specifically and individually set forth.

[0102] Unit dosage form In some embodiments, the pharmaceutical compositions described herein are formulated in unit dosage form. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for subjects (e.g., human subjects and other mammals), each unit containing a predetermined quantity of MMB compound active material calculated to produce a desired therapeutic effect, in association with a suitable pharmaceutical carrier.

[0103] In further embodiments, the unit dosage form comprises MMB dihydrochloride monohydrate Form II. In some embodiments, the unit dosage form comprises about 10 mg to about 1000 mg, about 10 mg to about 800 mg, about 10 mg to about 700 mg, about 10 mg to about 500 mg, about 10 mg to about 400 mg, about 10 mg to about 300 mg, about 10 mg to about 250 mg, about 10 mg to about 200 mg, about 10 mg to about 150 mg, about 10 mg to about 100 mg, about 10 mg to about 50 mg, about 50 mg to about 1000 mg, about 50 mg to about 800 mg, about 50 mg to about 700 mg, about 50 mg to about 500 mg, about 50 mg to about 400 mg, about 50 mg to about 300 mg, about 50 mg to about 250 mg, about 50 mg to about 20 In one embodiment, the compound contains an amount of MMB dihydrochloride monohydrate Form II equivalent to about 0 mg, about 50 mg to about 150 mg, about 50 mg to about 100 mg, about 100 mg to about 1000 mg, about 100 mg to about 800 mg, about 100 mg to about 700 mg, about 100 mg to about 500 mg, about 100 mg to about 400 mg, about 100 mg to about 300 mg, about 100 mg to about 250 mg, about 100 mg to about 200 mg, about 150 mg to about 300 mg, about 150 mg to about 250 mg, about 150 mg to about 200 mg, about 200 mg to about 300 mg, about 200 mg to about 250 mg, or about 200 mg to about 300 mg of MMB free base.

[0104] In certain embodiments of the present invention, the unit dosage form comprises at least one pharma- ceutically acceptable carrier. In other embodiments, the unit dosage form comprises MMB dihydrochloride monohydrate Form II, at least two diluents, at least one disintegrant, at least one glidant, at least one lubricant, and at least one antioxidant. In yet another embodiment, the unit dosage form comprises about 36%-44% MMB dihydrochloride monohydrate Form II, about 44%-58% diluent, about 4%-8% disintegrant, about 0.25%-0.75% glidant, about 1.2%-1.8% lubricant, and about 0.1%-0.5% antioxidant. In yet another embodiment, the at least two diluents are microcrystalline cellulose and lactose, the at least one disintegrant is sodium starch glycolate, the at least one glidant is colloidal silicon dioxide, the at least one lubricant is magnesium stearate, and the at least one antioxidant is propyl gallate. In yet another embodiment, the unit dosage form comprises about 36%-44% MMB dihydrochloride monohydrate Form II, about 30%-38% microcrystalline cellulose, about 14%-20% lactose, about 4%-8% sodium starch glycolate, about 0.25%-0.75% colloidal silicon dioxide, about 1.2%-1.8% magnesium stearate, and about 0.1%-0.5% propyl gallate.

[0105] The pharmaceutical compositions described herein can be prepared using any conventional method, including, but not limited to, mixing, dissolving, granulating, dragee making, levigating, emulsifying, encapsulating, entrapping, melt spinning, spray drying, or freeze drying processes. Those skilled in the art will recognize suitable methods and techniques for preparing tablets by conventional formulation. Exemplary methods and techniques for preparing powders for compression into tablets include dry granulation or wet granulation. Dry granulation generally refers to the process of forming granules without the use of liquid solution, while wet granulation generally refers to the process of adding liquid solution to powder to granulate.

[0106] Ruxolitinib treatment Aspects of the present disclosure include a method of treating a subject with MPN using MMB as a second-line treatment (e.g., as described herein). In some embodiments, the subject has been treated with a previous first-line JAK inhibitor treatment, such as ruxolitinib or fedratinib. Details of conventional ruxolitinib treatment in the SIMPLIFY 1 and 2 clinical trials are provided below.

[0107] Ruxolitinib is usually administered BID in equally divided doses. The recommended dose range for patients with myelofibrosis is 10x, from a maximum of 25 mg twice daily to a minimum of 5 mg once daily. The recommended starting dose of ruxolitinib is based on platelet count, with an attenuated starting dose of 15 mg twice daily recommended for patients with pretreatment platelet counts of 100-200 x 109 / L (Table 3). Complete blood counts (CBCs) and platelet counts are performed prior to initiating treatment and every 2-4 weeks until dose stabilization, then as clinically indicated. Doses may be titrated based on safety and efficacy. [Table 3]

[0108] 100×10 9 Ruxolitinib dose modification guidelines for hematologic toxicity for myelofibrosis patients initiating treatment with platelet counts of ≥ 50 × 10 / L include interrupting treatment and resuming dosing. 9 / L or less than 0.5 × 10 9 Intermittent treatment with absolute neutrophil count (ANC) less than 50 × 10 / L. 9 / L and platelet counts above 0.75 × 10 9 Administration may be resumed after recovery of ANC above 0.5×10 / L. 9 After treatment interruption for ANC less than 0.75 × 10 9 After recovery to ≥ 50 × 10 / L, resume treatment at a submaximal dose > 5 mg once daily or 5 mg twice daily in the week before treatment was discontinued. 9 Following interruption of treatment at a platelet count below 1 / L and recovery above this threshold, the maximum resumption doses are shown in Table 4. [Table 4]

[0109] If platelet counts decrease as outlined in Tables 5 and 6, consider a dose reduction of ruxolitinib, with the goal of avoiding dose interruptions for thrombocytopenia. [Table 5]

[0110] 50×10 9 / L~100×10 9 Ruxolitinib dose modification guidelines for hematologic toxicity for myelofibrosis patients initiating treatment with platelet counts below 25×10 / L include interrupting treatment and resuming dosing. 9 / L or less than 0.5 × 10 9 Intermittent treatment with ANC less than 35×10 9 / L and platelet counts above 0.75 × 10 9 Ruxolitinib may be resumed after recovery of ANC above 25 × 10 9 / L or less than 0.5 × 10 9 Dosing may be resumed at less than maximal doses of >5 mg once daily or >5 mg twice daily in the week preceding a decrease in ANC of less than 35 × 10 as described in Table 3. 9 Reduce the ruxolitinib dose for platelet counts < 1 / L. [Table 6]

[0111] It is to be understood that the invention is not limited to the particular embodiments described, which may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the invention will be limited only by the appended claims.

[0112] When a range of values ​​is provided, it is understood that each intervening value between the upper and lower limits of that range, and any other stated or intervening value within that stated range, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where a stated range includes one or both of the limits, ranges excluding either one or both of those included limits are also included in the invention.

[0113] In this specification, a certain range is indicated with a numerical value preceded by the term "about". The term "about" is used in this specification to provide literal support for the exact number it precedes and a number that is close to or approximately the number it precedes. When determining whether a number is close to or approximately a specifically stated number, the number that is close to or approximately the unstated number may be substantially equivalent to the specifically stated number in the context in which it is presented.

[0114] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative exemplary methods and materials are described herein.

[0115] It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should be further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as a prior basis for the use of exclusive terminology such as "solely," "only," or the use of "negative" limitations in connection with the recitation of claim elements.

[0116] All publications and patents cited herein are incorporated by reference as if each individual publication or patent was specifically and individually indicated to be incorporated by reference, and are incorporated by reference herein to disclose and describe the methods and / or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the publication dates provided may be different from the actual publication dates, which must be independently confirmed.

[0117] As will be apparent to one of ordinary skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the invention. Any described method can be carried out in the order of events described or in any other order that is logically possible. EXAMPLES

[0118] The following are examples of specific embodiments for carrying out the present invention. These examples are provided for illustrative purposes only and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to the numerical values ​​used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should naturally be allowed for.

[0119] Example 1: SIMPLIFY-1 and SIMPLIFY-2 Momelotinib (MMB) is a potent, selective, orally bioavailable small molecule inhibitor of JAK1, JAK2, and ACVR1 developed for the treatment of myelofibrosis (MF). However, in two phase 3 clinical trials (SIMPLIFY-1 and -2, respectively) for first- and second-line treatment of MF, MMB failed to meet all pre-specified secondary endpoints of TSS response in SIMPLIFY-1 and primary endpoint of SRR in SIMPLIFY-2.

[0120] The SIMPLIFY-1 trial (NCT01969838) assessed the efficacy and safety of MMB versus ruxolitinib (RUX) in patients naïve to JAK inhibitors and platelet counts 50 × 10 9 Patients with myelofibrosis with platelet counts ≥ 1 / L were studied. Patients (N=432) with high-risk, intermediate-2 risk, or symptomatic intermediate-1 risk myelofibrosis were treated with 200 mg MMB once daily or 20 mg RUX twice daily (or as labeled) for 24 weeks, after which all patients could receive open-label momelotinib. Efficacy was measured by splenic response, total symptom score (TSS), red blood cell transfusion rate, and transfusion independence or transfusion dependence, with the goal of demonstrating non-inferiority of MMB to RUX. The primary endpoint was at least a 35% reduction in spleen volume at 24 weeks compared with baseline.

[0121] In the SIMPLIFY-2 trial (NCT02101268), the efficacy and safety of MMB was studied in anemic or thrombocytopenic subjects with myelofibrosis previously treated with ruxolitinib (RUX). Efficacy was measured by splenic response, total symptom score (TSS), red blood cell transfusion rate, and transfusion independence or transfusion dependence, with the aim of demonstrating the superiority of MMB over BAT. Specifically, anemic or thrombocytopenic myelofibrosis patients who had been or had previously been treated (for at least 28 days) with (RUX) were studied for response to MMB versus best available treatment (BAT), primarily RUX (89% of patients) over a 24-week period, but without treatment or other standard interventions, after which all patients were able to receive long-term MMB treatment. Previously treated RUX patients who had grade 3 thrombocytopenia, anemia, and / or bleeding at grade 3 or worse, had a palpable spleen of at least 5 cm, and no peripheral neuropathy at grade 2 or worse, and required either red blood cell transfusion or a reduction in the dose of RUX, were included in the study. There was no lower limit for the required baseline platelet count. The primary endpoint was a reduction in spleen volume of at least 35% at 24 weeks compared with baseline.

[0122] Figures 8A-8B show schematics summarizing the parameters of two completed phase 3 trials of momelotinib (MMB) treatment of myelofibrosis: SIMPLIFY-1 and SIMPLIFY-2. Figure 8A: SIMPLIFY-1 trial of MMB in a first-line population not previously treated with a JAKi. In SIMPLIFY-1, the goal was non-inferiority to ruxolitinib (RUX) (MMB: N=215 subjects, RUX: N=217 subjects). Figure 8B: SIMPLIFY-2 trial in a second-line population of anemic or thrombocytopenic subjects previously treated with RUX (red blood cell (RBC) transfusions with RUX=64%. RUX dose adjustments: for thrombocytopenia=21%; for anemia / hematoma=35%). In SIMPLIFY-2, the goal was to be superior to best available treatment (BAT) (MMB: N=104 subjects, BAT: N=52 subjects). For both SIMPLIFY-1 and SIMPLIFY, primary endpoint: ≥35% reduction in spleen volume at 24 weeks. Secondary endpoints: Total Symptom Score (TSS) response at 24 weeks. Impact on RBC transfusion requirements.

[0123] The first analysis of the results of the SIMPLIFY-1 trial was reported by Mesa et al. (SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients with Myelofibrosis”, J. Clinical Oncology 2017,35(34):3844-3850). Their analysis of the SIMPLIFY-1 trial data showed that momelotinib was non-inferior to RUX for reducing spleen size in JAKi-naive patients, thus meeting the primary endpoint of the study. However, despite evidence of a demonstrable symptomatic benefit of momelotinib in symptomatic patients in that study, non-inferiority was not demonstrated for the secondary endpoint of total symptom score (TSS) response. MMB treatment was associated with an increased rate of transfusion independence, a decreased rate of transfusion dependence, and a decreased transfusion rate compared to RUX, all of which were nominally statistically significant.

[0124] The results of the SIMPLIFY-2 trial were reported by Harrison et al. ("Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY2): a randomised, open-label, phase 3 trial." Lancet Haematol; Vol. 5, No. 2, February 2018, pp. e73-e81). Interpretation of the SIMPLIFY-2 trial data presented with momelotinib showed that it was not superior to BAT in reducing spleen size, and therefore the trial did not meet its primary endpoint.

[0125] Although key secondary endpoints were nominally significant in the analysis by Harrison et al., these were not considered statistically significant in the hierarchy of analytical endpoints. In general, patients in the momelotinib group had greater total symptom score (TSS) responses, fewer transfusions, greater transfusion independence, and less transfusion dependence compared with patients in the BAT group. The initial analysis was complicated by the lack of the possibility or tolerance of discontinuation of ruxolitinib prior to the start of randomized study treatment. By not including a mandatory washout from prior ruxolitinib, assessment of splenic response was unclear for subjects in either group in this study. Furthermore, patients enrolled in this study were not selected based on splenic progression on RUX.

[0126] Example 2: Reanalysis of SIMPLIFY-1 and SIMPLIFY-2 Reanalysis of data from the SIMPLIFY-1 and SIMPLIFY-2 trials demonstrated that momelotinib reduced thrombocytopenia in patients with thrombocytopenia of 150 × 10 per liter without momelotinib dosing causing thrombocytopenia and therefore without the need for dose reductions or interruptions due to thrombocytopenia. 9 We found it to be effective in reducing spleen size (SSR), improving total symptom score (TSS), and improving transfusion independence in patients with below platelet counts. Our reanalysis shows that MMB is effective in JAKi-naïve patients and as second-line treatment for RUX, reducing splenomegaly, improving symptoms associated with myelofibrosis, and increasing transfusion independence rates in a patient population with or at risk for thrombocytopenia from underlying disease and current standard of care.

[0127] Platelet levels during MMB or RUX treatment Figure 31 shows a plot of the mean (± standard error) platelet counts of MMB versus RUX subjects in the SIMPLIFY1 study over the 24-week double-blind treatment phase. The mean platelet counts of RUX patients are clearly lower than the mean platelet counts of MMB patients.

[0128] FIG. 32 shows a plot of the mean (± standard error) platelet counts over time in the double-blind and open-label treatment phases of MMB versus RUX of the SIMPLIFY 1 study (Intention-to-Treat (ITT) analysis).

[0129] FIG. 33 shows a plot of the mean (± standard error) platelet counts over time during the randomized and chronic treatment phases of MMB versus best available treatment (BAT) of the SIMPLIFY2 trial (intent to treat (ITT) analysis).

[0130] Figures 31-33 show plots of mean platelet counts for MMB vs. RUX subjects in the SIMPLIFY1 study, which show that subjects treated with MMB were able to maintain platelet levels during treatment, e.g., during the 24-week double-blind study phase. In comparison, RUX subjects showed a significant decrease in platelet counts from baseline, which can often lead to a required dose reduction (e.g., as described herein). Thus, MMB subjects were at lower risk of developing thrombocytopenia (e.g., grade 3 or 4 thrombocytopenia) or having to reduce doses undesirably, since the subjects were able to maintain their platelet counts for the most part during treatment.

[0131] Figures 32-33 also show the ability of MMB to restore platelets when switched from RUX to MMB after 24 weeks.

[0132] Figure 34 shows a plot of the average daily dose in SIMPLIFY1 by group for each week of the study during the 24-week double-blind treatment phase. The vertical bars represent the percentage of subjects receiving the various doses. The majority of MMB subjects received 200 mg per day throughout the course of the study. In the RUX group, less than half of the subjects received the standard 40 mg / day (20 mg BID), and about a quarter received only 10 mg / day (5 mg BID).

[0133] Figure 35 shows a plot of the mean daily dose in SIMPLIFY2 by group for each week of the study during the 24-week randomized treatment phase. The vertical bars represent the percentage of subjects receiving various doses. The majority of MMB subjects received 200 mg per day throughout the course of the study. In the BAT group, the most common dose throughout the course of the study was 20 mg / day (10 mg BID), followed by 10 mg / day (5 mg BID). A very small number of subjects (approximately 10%) received 40 mg / day (20 mg BID).

[0134] Figures 34-35 show dose breakdown by treatment for treated patients in the SIMPLIFY 1 or 2 studies, respectively, and demonstrate that there was a reduction in RUX dose (dose reduction) and relative stability of MMB dose levels over the 24-week treatment period.

[0135] Patient Response by Baseline Platelet Count Subgroups SIMPLIFY1(S1) The SIMPLFY1 clinical trial data were reanalyzed for subgroups of subjects with specific baseline platelet counts in the MMB and RUX arms of the study.

[0136] Patient data were analyzed according to the following baseline platelet count (PLT) subgroups, specifically: 150 × 10 9 The analysis was conducted according to the threshold PLTs per liter: 1) PLT < 50 × 10 9 / L;2)50×10 9 / L≦PLT<100×10 9 / L;3)100×10 9 / L≦PLT<150×10 9 / L. Reanalysis data are shown in Table 13 (SIMPLIFY1). Selected data are also shown in the figure below.

[0137] The data presented in Tables 7-9 generally indicate that for each endpoint (TSS, SRR, and TI rate at week 24), the response rate in RUX was significantly higher than in ITT response rates in subgroup 2 (50 × 10 9 / L), the efficacy of the drug tends to decrease (becomes less effective) (50×109 / L≦PLT<100×10 9 / L) and 3 (100 × 10 9 / L≦PLT<150×10 9 / L), with most results outside the 95% CI of the results achieved for each endpoint. Response rates (TSS ≥ 6, or TSS ≥ 10) in RUX subjects who were symptomatic at the start of RUX treatment (TSS) are consistent with this observation.

[0138] The analysis showed that efficacy (SRR, TSS, TI) was reduced or significantly reduced with RUX in patients with low platelet counts (subgroups 2–3), with platelets >50K×10 9 / L (subgroup 1) (not shown). [Table 7] [Table 8] [Table 9]

[0139] Tables 10-12 show an analysis of data for the MMB arm of SIMPLIFY 1 by baseline platelet count corresponding to Tables 7-9. The data presented in Tables 10-12 generally show that for each endpoint (TSS, SRR, and TI rate at week 24), the response rate of MMB was significantly higher than that of ITT response rate in subgroup 2 (50 × 10 9 / L≦PLT<100×10 9 / L), and subgroup 3 (100 × 10 9 / L≦PLT<150×10 9 / L), with most results remaining within the 95% CI of the results achieved for each endpoint. The response rates (TSS ≥ 6 or TSS ≥ 10) in MMB subjects who were symptomatic at the start of MMB treatment are consistent with this observation. [Table 10] [Table 11] [Table 12]

[0140] In contrast to the generally worsening responses shown for RUX patients, MMB subjects in subgroups 3 and 2 generally demonstrated stable efficacy (e.g., TSS and TI rates at week 24) compared with responses of all patients.

[0141] Although the splenic response rate (SRR) in subgroup 3 (Table 11) was below the determined response for all MMB and subgroup 2 patients, the SRR rate in this subgroup 3 was still higher with MMB versus RUX for this subgroup.

[0142] Figure 36 shows a graph of the spleen response rate (SRR) at Week 24 versus baseline platelet count subgroups for all MMB or RUX patients treated with the SIMPLIFY1 study. Horizontal bars indicate the 95% confidence interval for the mean response of all patients (all points).

[0143] Figures 37-38 show graphs of spleen response rate (SRR) at week 24 versus baseline platelet count subgroups for symptomatic (e.g., TSS ≥ 6 or ≥ 10, respectively) MMB or RUX patients treated with the SIMPLIFY1 trial. Horizontal bars indicate 95% confidence intervals for the mean response of all patients (all points).

[0144] Figures 42-44 show similar results for transfusion-dependent to transfusion-independent conversion rates at week 24. Figures 39-41 show similar results for symptomatic response rates (TSS). Figures 45-47 show similar results for TI responses at week 24.

[0145] These graphs and tables show that momelotinib treatment was associated with a 150×10 9 Figure 36 shows that JAKi-naïve myelofibrosis patients with baseline platelet counts of 150×10 / L or less can be provided with the desired therapeutic benefit. 9 / L or less, e.g. 100×10 9 The results show that the splenic response rate (SRR) of MMB patients in the SIMPLIFY1 study was superior to that of RUX patients when the mean splenic response rate (SRR) was 1.2 / L or less. The advantage of MMB over conventional RUX treatment was shown to be more pronounced when subjects were also symptomatic at the start of treatment, e.g., when subjects had a total symptom score (TSS) of 6 or more (Figure 37), e.g., 10 or more (Figure 38). Similar advantages were found for transfusion-dependent to independent conversion rates (Figures 42-44) and symptomatic response rates (Figures 39-41).

[0146] SIMPLIFY2(S2) The SIMPLFY2 clinical trial data were reanalyzed for subgroups of subjects with specific baseline platelet counts in the MMB versus BAT arms of the study.

[0147] Specifically, according to the following baseline platelet count (PLT) subgroups: 150 × 10 9 / L:1) PLT<50×10 9 / L;2)50×10 9 / L≦PLT<100×10 9 / L;3)100×10 9 / L≦PLT<150×10 9 Patient data were analyzed according to the threshold PLT of 100 / L. The reanalyzed data are shown in Table 14 (SIMPLIFY2).

[0148] From the SIMPLIFY2 data, platelets were 50 × 10 9 It has been shown that MMB can be administered at full doses in patients regardless of platelet count, including those with platelet counts below 50 × 10 / L. Efficacy results for SRR, TSS, and TI ranged from 50 to 100 × 10 9Patients with platelets / L (subgroup 2) were maintained with MMB and had a platelet count of 100–150 × 10 9 / L platelets (subgroup 3) were maintained for TSS and TI endpoints.

[0149] The SIMPLIFY2 study was an overall smaller study (less than one-third the size of SIMPLIFY1) and therefore had smaller numbers of patients in all baseline platelet count subgroups, with more inherent variability across results.

[0150] In general, the analyses in Table 14 show that for all endpoints except SRR, the 150 × 10 9 The baseline platelet count subgroups below 100 × 10 / L show superior outcomes for MMB subjects compared with BAT subjects. For example, baseline platelet count subgroup 3 (100–150 × 10 9 For MMB subjects on 10 mg / L, the conversion rate from transfusion dependence to independence at 24 weeks was 46% compared with 9% for BAT subjects.

[0151] These results are generally consistent with those presented above for SIMPLIFY 1. However, due to inherent variability in the data from the smaller SIMPLIFY 2 study, no conclusions could be drawn regarding the magnitude of clinical benefit provided by MMB treatment in the subgroup of patients with low baseline platelet counts. [Table 13] [Table 14]

[0152] A detailed analysis and characterization of the SIMPLIFY-1 and SIMPLIFY-2 results is presented below.

[0153] SIMPLIFY1 results: Momelotinib activity against splenomegaly: 26.5% SRR. Momelotinib was statistically non-inferior to RUX of the spleen (p=0.011).

[0154] Momelotinib demonstrated deeper splenic responses after RUX crossover. Deepened response: 46.2% splenic response (SRR) at any time during the open-label phase (momelotinib group). Benefit after RUX: 16.5% of subjects did not achieve a splenic response with ruxolitinib but did so after 24 weeks of additional momelotinib treatment (crossover group).

[0155] Figure 9 shows a graph of the median baseline and 24-week mean median symptom scores assessed as the 4-week average of the daily symptom scores for the seven individual symptoms that make up the total symptom score (TSS) in the SIMPLIFY1 study, showing that momelotinib provided clinically equivalent symptom benefits to RUX. Both momelotinib and ruxolitinib substantially improved all symptoms compared to baseline in a clinically equivalent manner (MMB slightly lost total symptom score (TSS) non-inferiority to RUX in SIMPLIFY-1: 28.4% vs. 42.2% (proportional difference for non-inferiority 0.00 (-0.08, 0.08))). The higher mean and median baseline TSS in MMB vs. RUX indicates an imbalance in baseline scores due to lack of stratification, creating the need to achieve a larger absolute reduction in TSS in the MMB group to achieve a response.

[0156] FIG. 10 shows rapid and sustained hemoglobin improvement in patients following initiation of MMB, and similar rapid and sustained hemoglobin improvement in subjects randomized to ruxolitinib following momelotinib crossover after 24 weeks of SIMPLIFY1.

[0157] Momelotinib was well tolerated in patients with myelofibrosis in the SIMPLIFY 1 trial. The rate of anemia was 14% with momelotinib and 38% with RUX. The rate of grade 3 or higher anemia was 6% with momelotinib and 23% with RUX.

[0158] Momelotinib had a similar overall safety profile to ruxolitinib in SIMPLIFY-1, showing significantly lower rates of thrombocytopenia and anemia. Rates of adverse events (AEs) were generally similar, although fewer patients experienced AEs and fewer patients experienced grade 3 or 4 AEs with momelotinib versus ruxolitinib.

[0159] Trends in leukemia-free survival (LFS) and overall survival (OS) favored momelotinib over ruxolitinib (mLFS / mOS not reached).

[0160] SIMPLIFY2 results: Momelotinib showed significant symptomatic activity compared to BAT (approximately 90% ruxolitinib) in second-line patients, with statistically significant symptomatic response (p<0.001): TSS of 26.2% with momelotinib vs. 5.9% with best available treatment (BAT).

[0161] Trends in LFS and OS favor momelotinib over best available therapy. mOS for MMB is 28 months. Momelotinib provided noteworthy post-RUX survival compared with a historical control survival of 14 months reported in ruxolitinib-treated patients (Newberry et al.,2017 Blood 130(9):1125-1131).

[0162] Momelotinib exhibits differential activity against anemia and transfusions. In SIMPLIFY1, momelotinib promoted and maintained transfusion independence in 66% of patients compared to 49% in RUX. Statistically significant transfusion independence (TI) rates (p<0.001). In SIMPLIFY2, momelotinib prevented the need for transfusions: 32.8% of patients who were transfusion-dependent (TD) at baseline were TI at week 24 with momelotinib compared to 3.7% in BAT. In SIMPLIFY2, momelotinib promoted and maintained transfusion independence: 43% of patients were TI at week 24 with momelotinib compared to 21% in BAT.

[0163] The SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials show that momelotinib provided maintained transfusion independence (TI).

[0164] Phase 3 trials, SIMPLIFY-1 and SIMPLIFY-2, show that momelotinib induced a switch from transfusion dependence to independence (over 12 weeks): in SIMPLIFY-1, the transfusion independence rate over 12 weeks was 49.1%. In SIMPLIFY-2, the transfusion independence rate over 12 weeks was 46.6%.

[0165] Phase 3 trials, SIMPLIFY-1 and SIMPLIFY-2, show that momelotinib resulted in conversion from transfusion dependence to independence (over 8 weeks): in SIMPLIFY-1, the transfusion independence rate over 8 weeks was 58.5%. In SIMPLIFY-2, the transfusion independence rate over 8 weeks was 46.6%.

[0166] A combined study-wide analysis of the ratio of transfusion independence to dependence at 12 weeks / 8 weeks indicates that the transfusion independence rate at 12 weeks or greater was 44.1% and the transfusion independence rate at 8 weeks or greater was 48.7% (Combined TI response rates in TD patients (n=152) from SIMPLIFY-1, SIMPLIFY-2, and '1672. This aggregate data represents a range of patients with intermediate- / high-risk MF. [Table 15]

[0167] Figure 11 is a graph showing that hepcidin consistently reduced momelotinib after MMB administration. Translational biology phase 2 study (N=41; GS-US-352-1672). The 12-week transfusion independence (TI) response rate was 34%, indicating a clinically valid mechanism of decreased ACVR1 activity and hepcidin, and increased iron and hemoglobin.

[0168] Figure 13 is an exemplary timeline of high levels of iron and hemoglobin after initiation of momelotinib treatment. Momelotinib treatment reduces hepcidin, leading to increased serum iron and transferrin within 2 weeks, providing iron mass to erythroblasts to promote erythrocyte maturation. As erythropoiesis is restored, iron levels subsequently normalize, while hemoglobin, RBCs, and platelets continue to increase through week 24.

[0169] Translational Biology Research In a translational biology study, we determined the effects of momelotinib on plasma hepcidin, markers of iron stores and availability, erythropoiesis, and inflammation, and explored the mechanism of momelotinib's favorable effects on MF-associated anemia and transfusion independence. See Oh et al. “Hepcidin Suppression by Momelotinib Is Associated With Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients”, Abstract #4282:Presented at ASH 60th Annual Meeting&Exposition:December 1-4,2018,San Diego,CA, the disclosure of which is incorporated herein by reference.

[0170] Figure 12 shows a schematic of the exploratory translational biology study. Populations: Primary MF (PMF), Post-Polycythemia Vera MF (Post-PV MF), or Post-Essential Thrombocythemia MF (Post-ET MF). MF treatment required (investigator opinion). High risk or intermediate-2 (DIPSS). Transfusion dependent (TD) at baseline. [defined as ≥4U red blood cell (RBC) transfusion 8 weeks prior to first dose of MMB]. Objectives: Exploratory translational biology study (MMB: N=41 subjects). Objectives: Primary objective: Determine transfusion independence response rate (TI; ≥12 weeks and ≥8 weeks) in TD subjects with MF treated with momelotinib. Secondary objectives: To assess baseline levels and changes in iron metabolism markers; To assess inhibition of JAK1 / 2; To evaluate the pharmacokinetics of momelotinib in transfusion-dependent patients with MF; and To evaluate changes in circulating cytokines and inflammatory markers. [Table 16]

[0171] FIG. 14 shows a graph illustrating the increases in iron and hemoglobin levels observed overall and for transfusion-independent responders (TI-R) to MMB treatment.

[0172] result Primary endpoint: Transfusion independence rate for 12 weeks or more was 34.1%. Secondary endpoint: Transfusion independence rate for 8 weeks or more was 39.0%.

[0173] Anemia Benefit in TI-NR Patients. Reduction in transfusion burden (≥50%) in TI-NR patients was observed in 77.8% of cases (≥2 RBC units reduction) in any 8-week period.

[0174] Example 3: Kinetic and Time-To-Event analyses show a significant reduction in transfusion requirements in Janus kinase inhibitor-naïve myelofibrosis patients treated with momelotinib in direct comparison with ruxolitinib.

[0175] Momelotinib (MMB) is a potent, selective, orally bioavailable small molecule inhibitor of JAK1, JAK2, and ACVR1 developed for the treatment of intermediate- and high-risk myelofibrosis (MF). Systemic inflammation, essential to the pathogenesis of MF, leads to increased ACVR1 activity, which in turn increases hepcidin secretion, resulting in disturbed iron homeostasis and iron-restricted anemia (Ganz T. “Systemic Iron Homeostasis:,Physiol Rev.2013;93:1721-41; and Langdon JM,Yates SC,Femnou LK et al.“Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation”,Am J Hematol. 2014;89:470-9). MMB inhibition of ACVR1, unique among the JAK inhibitor (JAKi) class, leads to reduced hepcidin, restoration of iron homeostasis and RBC production, and alleviation of anemia and transfusion dependency (TD). Chronic and progressive anemia is a key feature of MF. Anemia and TD strongly predict poor survival (Pardanani A, Finke C, Abdelrahman RA, Lasho TL and Tefferi A.“Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis.” Am J Hematol. 2013;88:312-6).In contrast to ruxolitinib (RUX), which leads to exacerbation, MMB is the only clinical-stage JAKi with potent ACVR1 inhibitory activity that leads to improvement of anemia.

[0176] A double-blind, active-controlled phase 3 trial, the SIMPLIFY-1 (S1) study, in which 432 patients received randomized treatment with MMB or RUX for 24 weeks, was previously reported (Mesa RA, Kiladjian JJ, Catalano J V. et al. “Simplify-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis”, Journal of Clinical Oncology, 2017;35:3844-50). In addition to a significant reduction in splenomegaly and improvement in systemic symptoms, the study showed that patients in the MMB group achieved nominal statistical significance for all anemia endpoints tested, including a higher rate of transfusion independence (p<0.001) and a lower rate of TD (p=0.019) at 24 weeks compared with patients in the RUX group, consistent with the erythropoiesis-promoting effect of MMB. Overall, a clear reduction in transfusion requirements was observed in patients receiving MMB versus RUX.

[0177] Because transfusion burden is a significant concern for clinicians and patients, the S1 data were further explored with statistical models utilizing a variety of novel anemia benefit endpoints, including time to transfusion and transfusion intensity over time, to better understand the dynamics of RBC transfusion. We calculated the proportion of patients with 0 and 4 transfusions and also performed time-to-event analyses examining the time to first unit transfused and the time to 5th unit transfused. Because transfusions typically consist of two units, the 5th unit transfused effectively represents a 3rd transfusion event. The number of units transfused was also considered a recurrent event and examined with and without patient baseline characteristics as covariates. Finally, the proportion of subjects with no transfusion burden and mean transfusion rates were compared between treatment groups using a mixture model based on the zero-inflated negative binomial (ZINB) distribution fitted to the transfusion data.

[0178] Kaplan-Meier estimates of the proportion of patients who required no transfused units during the 24-week randomized treatment period were 73% and 46% for MMB and RUX, respectively (p<0.0001; Figure 29), whereas the proportion of patients who required 4 units or less was 83% and 62% (p<0.0001). When examining units transfused as a recurrent event, patients receiving MMB had approximately half the hazard ratio versus patients on RUX in both models with and without patient baseline characteristics as covariates (HR 0.522; p<0.0001). The ZINB covariate model showed that MMB increased the odds of zero units being transfused in the first 24 weeks by 9.3 times versus RUX (p<0.0001).

[0179] In summary, the novel dynamic and time-to-event analysis methods described are related to and are a valuable addition to standard measurements of transfusion burden in patients with MF.The results of these analyses allow for a more detailed description of the differential anemia benefits of MMB compared to RUX in a double-blind study of JAKi-naive patients.Combined with additional data from the SIMPLIFY study, these results show that MMB can address three characteristic features of MF, namely splenomegaly, systemic symptoms, and anemia, and differentiate it from other JAK inhibitors.

[0180] Example 4: MOMENTUM clinical research We will conduct a randomized, double-blind, phase 3 study to evaluate the activity of momelotinib (MMB) versus danazol (DAN) in patients with primary myelofibrosis (PMF), post-polycythemia vera (PV), or post-essential thrombocythemia (ET) myelofibrosis previously treated with JAK inhibitor therapy (MOMENTUM trial). We will evaluate the benefit of MMB in reducing transfusion burden. In addition to assessing systemic symptoms, splenomegaly, and anemia, MOMENTUM will further evaluate the association between anemia benefit and patient-reported measures of clinical benefit.

[0181] Momerotinib (MMB), or N-(cyanomethyl)-4-(2(4-morpholinophenylamino)pyrimidin-4-yl)benzamide, dihydrochloride monohydrate, is the active ingredient.

[0182] Primary Objective: To determine the efficacy of MMB versus DAN as assessed by improvement in Myelofibrosis Symptom Assessment Form v4.0 (MFSAF) Total Symptom Score (TSS) in subjects with PMF, post-PV myelofibrosis (MF), or post-ET MF previously treated with approved JAK inhibitor therapy.

[0183] Secondary Objectives: To compare the effect of MMB versus DAN on transfusion independence (TI) status at 24 weeks To compare the SRR in subjects treated with MMB vs. DAN To compare the RBC transfusion requirements of subjects treated with MMB versus DAN To evaluate the duration of MFSAF TSS reactions -To evaluate the duration of TI status at 24 weeks To compare the benefits of MMB versus DAN on anemic response and transfusion requirements To compare change from baseline MFSAF TSS at week 24 for subjects treated with MMB vs. DAN Characterizing the safety of MMB To compare overall survival (OS) and leukemia-free survival (LFS) in subjects treated with MMB versus DAN To evaluate the association between MMB exposure (pharmacokinetics [PK]) and outcomes · Any other secondary objectives as defined in the Protocol.

[0184] Exploratory purpose: To evaluate time to splenic progression for subjects treated with MMB vs. DAN Other exploratory endpoints.

[0185] Test Design: This is a randomized, double-blind study to confirm the differential clinical benefit of MMB versus DAN in subjects who have received approved Janus kinase (JAK) inhibitor treatment for MF for a minimum of 90 days, or for a minimum of 28 days if JAK inhibitor treatment was complicated by the need for RBC transfusion ≥4 units at week 8 or by grade 3 / 4 adverse events (AEs) of thrombocytopenia, anemia, or hematoma. Subjects must have a MFSAF TSS of ≤10 at screening and be symptomatic with anemia with hemoglobin (Hgb) <10 g / dL.

[0186] For subjects with ongoing JAK inhibitor treatment at screening, JAK inhibitor treatment must be tapered over at least 1 week, followed by a 2-week non-treatment interval that ends prior to randomization. A 7-day baseline period (Days BL1-BL7) is required prior to randomization during which daily symptom scores are obtained. For subjects who have tapered and discontinued a previous JAK inhibitor and are beginning this 14-day non-treatment interval, the 7-day baseline period will begin only after the 1-week non-treatment interval is completed. Study treatment on Day 1 will occur within 3 days after randomization.

[0187] Subjects will receive oral randomization treatment, MMB and DAN placebo, or DAN and MMB placebo.

[0188] Subjects will remain blinded to their randomized treatment assignment whenever possible. To allow for a decision on which patients are eligible to start open-label MMB, for example, a blinding process should be followed. After completion of all 24-week assessments, subjects will be given the choice to receive MMB in the open-label extension treatment period, except for subjects who discontinue blinded study treatment before the completion of 24 weeks if the blinding confirms that the patient is receiving MMB. Prior to 24 weeks, subjects will discuss with the investigator or designee whether they would like to receive open-label MMB after completing 24 weeks. Except for subjects who discontinue early from the MMB group, subjects may begin open-label MMB and continue treatment until the end of 204 weeks: a) at the end of 24 weeks if they have completed the randomized treatment period and all 24-week assessments, b) at the end of 24 weeks if they have discontinued treatment with DAN before the end of 24 weeks but have continued study assessments and have not received prohibited drugs, and c) at any time during the randomized treatment period if they meet the protocol-defined criteria for confirmed symptomatic splenic progression. Open-label treatment with MMB may continue through the end of week 204. Transition to an MMB extension study, if available, may occur once subjects have completed at least 48 weeks on study.

[0189] Subjects randomized to receive DAN who receive clinical benefit at the end of 24 weeks may continue open-label DAN treatment through week 48. The decision to continue DAN or cross over to MMB must be made by the end of 24 weeks.

[0190] Analysis of the primary efficacy endpoint will be performed when the outcome of the primary endpoint is determinable for all subjects, i.e., when each subject has completed the randomized treatment period or has dropped out. The maximum duration of participation in the study, including screening, randomization treatment, open-label extension treatment, safety follow-up, and survival follow-up periods, is approximately 7 years. During the conduct of the study, a Data Monitoring Committee (DMC) will review the interim progress of the clinical trial, safety data, and clinical efficacy endpoints, and make recommendations to the sponsor regarding the continued conduct of the study. The DMC will be asked to advise the sponsor regarding the future conduct of the trial, but the sponsor will retain the final decision-making authority regarding all aspects of the trial.

[0191] After screening and baseline periods, the study will begin with a 24-week randomized treatment period during which data will be collected for the primary efficacy analysis. Subjects will be randomized on a 2:1 basis (MMB and DAN placebo:DAN and MMB placebo) and stratified by baseline MFSAF TSS, baseline palpable spleen length below the left costal margin, baseline RBC units transfused in the 8 weeks prior to randomization, and study site.

[0192] Blinded treatment (MMB and placebo or DAN and placebo) may be interrupted and / or reduced due to thrombocytopenia, neutropenia, non-hematopoietic or other toxicity according to protocol-specified criteria. Continuation of treatment at a reduced dose is preferred to discontinuation of treatment, but study treatment will be discontinued, at the sponsor's discretion, if disease progression or toxicity is observed that impairs the ability to continue treatment and / or certain procedures of the study necessary for safe continuation of treatment. Subjects with confirmed symptomatic splenic progression as defined according to the protocol or leukemic transformation will discontinue study treatment. Subjects randomized for DAN may be crossed over to MMB at any time during the randomized treatment period if they meet protocol-defined criteria for confirmation of symptomatic splenic progression.

[0193] If a subject discontinues treatment, every attempt will be made to continue all study evaluations according to the event schedule (including transfusion records, symptom assessments, and patient-reported outcomes [PROs]) until the end of 24 weeks and to conduct follow-up procedures, including safety follow-up visits and survival follow-up assessments.

[0194] A subject should only be withdrawn from the study if it is impossible or acceptable to the subject or the investigator for the subject to continue study evaluations after treatment is discontinued.

[0195] Methodology: Screening and Baseline Assessment: After informed consent is obtained, screening activities begin. Screening evaluations include a serum pregnancy test for women of childbearing potential (WOCBP), laboratory tests (chemistry, CBC with differential, and urinalysis), virology screening, physical examination including disease-related clinical signs, vital signs, 12-lead electrocardiogram (ECG), Dynamic International Prognostic Scoring System (DIPSS, or DIPSS-plus) disease assessment, and Eastern Cooperative Oncology Group (EGOG) performance status. Recording of AEs and serious adverse events (SAEs) begins at the time of signing of the informed consent form (ICF). Medical and medication history is recorded, including last history of JAK inhibitor treatment, last spleen volume measurement, and best splenic response during previous treatment (response, stable disease, or splenic progression according to IWG criteria). Recording of concomitant medications begins, including the use of a subject-completed narcotic pain medication log. Records of RBC transfusions will be initiated, including pre-transfusion Hgb concentration and documentation of whether transfusions were given due to factors such as clinically evident bleeding or accident / injury. Transfusion history and pre-transfusion Hgb concentration for the 12 weeks prior to randomization will be collected from the subject's records. Subjects will be trained in the use of an ePRO device given to them. The ePRO device is physical hardware used by patients to collect PRO data daily at home and at study visits. To determine eligibility, the MFSAF will be completed in 1 day using the ePRO device in situ. Daily MFSAF assessments using the ePRO device will be completed by the subject at home for 7 consecutive days immediately prior to randomization to determine baseline MFSAF TSS.

[0196] At baseline, a urine pregnancy test (for WOCBP) will be performed along with laboratory tests (chemistry, CBC with differential, urinalysis, and blood samples for exploratory evaluation including mutation analysis), physical examination including disease-related clinical signs, vital signs, ECOG performance status, and ongoing records of AEs and SAEs, RBC transfusions, and concomitant medications.Baseline spleen length measurements for stratification will be performed by palpation (or ultrasound) as part of the physical examination.

[0197] To provide a consistent baseline assessment of spleen volume, a baseline magnetic resonance imaging (MRI) scan, or computed tomography (CT) scan if the subject is unable to undergo an MRI, should be performed within the following time periods: for subjects receiving any active MF treatment (including JAK inhibitors) known to reduce spleen size at screening, the scan should be performed within 1 week (preferably within 3 days, if possible) prior to Day 1, and for subjects not receiving any active MF treatment known to reduce spleen size at the start of the screening period, the scan should be performed within 14 days prior to the first dose of study treatment (Day 1). However, the results of the scan are not required prior to starting study treatment.

[0198] MFSAF baseline assessments are completed electronically at home using the ePRO device. Daily assessments are completed for 7 consecutive days (BL1-BL7) immediately prior to randomization. If more than 3 MFSAF TSS results are missing on any one day from this 7-day assessment period, the score is considered missing and the subject should not be randomized. Therefore, if a site is notified that a subject has missed a baseline MFSAF day, it is important to contact the subject immediately and advise them of the importance of completing daily assessments. If a baseline MFSAF is missed for reasons other than subject non-compliance (e.g., technical issues with the ePRO device), the sponsor should be contacted for guidance.

[0199] Baseline assessments will be completed electronically using an ePRO device during an on-site visit for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function, Patient Perception of Global Severity (PGIS), and EuroQoL Five Dimension (EQ-5D).

[0200] First day of study treatment (Day 1): The first dose of study treatment (Day 1) will be administered within 3 days after randomization. Subjects must remain for observation for a minimum of 4 hours after the first dose, and antihypertensive therapy should not be discontinued until at least 4 hours after administration of study treatment on the first dose day. Study procedures on Day 1 include distribution of study treatment, physical examination, vital signs, ECG, ECOG performance status, as well as daily MFSAF recording and initiation of daily study treatment self-administration.

[0201] Efficacy assessment: To assess transfusion status, RBC transfusion history, including pre-transfusion Hgb concentration, will be collected from the subject's records for 12 weeks prior to randomization and at each visit until discontinuation. During the randomized treatment period, transfusions and CBCs will be recorded at least every 4 weeks, even if the subject discontinues treatment. During the open-label extension treatment period, transfusions and CBCs will continue to be recorded at each study visit until the end of Week 96 or until discontinuation.

[0202] PRO questionnaires will be completed electronically on a periodic basis. The MFSAF will be completed daily using an ePRO device during the last 7 days (± 7 days) of each 4-week period during the randomized treatment period and during weeks 25 through 48 of the open-label extension treatment period. Subjects who discontinue treatment before week 24 will continue daily MFSAF assessments until the end of the 24-week period.

[0203] Clinical, laboratory, and disease assessments (including ECOG performance status and MF symptom assessment), as well as ongoing documentation of RBC transfusions, will be completed at routine visits.

[0204] Spleen volumes will be assessed at the end of weeks 24 and 48 as needed to ascertain splenic progression.

[0205] Leukemia-free survival and OS will be assessed during survival follow-up.

[0206] Safety Assessment: Recording of AEs and SAEs will begin upon signing of the ICF and continue until 30 days after the last dose of study treatment. Concomitant medications, laboratory tests (chemistry, CBC with differential, and urinalysis), urine pregnancy test, 12-lead ECG, physical examination (including measurement of splenic length by palpation or ultrasound), and vital signs will be completed at the visit.

[0207] Exploratory evaluation: Additional exploratory data will be collected at various time points.

[0208] Pharmacokinetic Evaluation: Blood samples for PK analysis will be collected at various time points.

[0209] Number of subjects: Initially 180 subjects, may increase to a maximum of 270.

[0210] Main criteria for diagnosis and inclusion: Symptomatic anemic patients with PMF, post-PV MF, or post-ET MF who have been previously treated with approved JAK inhibitor therapy.

[0211] Inclusion criteria: 1. Age 18 or older 2. Confirmed diagnosis of PMF according to the World Health Organization (WHO) 2016 criteria or post-PV / ET MF according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria 3. Symptomatic, defined as MFSAF TSS ≥ 10 units as assessed by a single MFSAFv4.0 assessment at screening examination 4. Anemia, defined as any of the following: - For any subject, received a blood transfusion within 28 days prior to the first day of baseline assessment (BL1) and had a pre-transfusion Hgb of <10 g / dL, or - Hgb <10 g / dL during baseline (BL days 1-7) for subjects not on ongoing JAK inhibitor therapy at screening, or For subjects receiving ongoing JAK inhibitor treatment at screening, Hgb <10 g / dL during screening prior to initiation of JAK inhibitor taper 5. Previously treated with an approved JAK inhibitor for PMF or post-PV / ET MF for ≥90 days, or ≥28 days if JAK inhibitor treatment was complicated by the need for RBC transfusion ≥4 units at week 8 or by a grade 3 / 4 adverse event (AE) of thrombocytopenia, anemia, or hematoma - Subjects who discontinued JAK inhibitor treatment prior to screening do not require an additional non-treatment interval - For subjects on JAK inhibitor treatment at screening, JAK inhibitor treatment must be tapered over at least 1 week, with the off-treatment interval beginning 7 days prior to BL1 (the first of 7 consecutive days of baseline MFSAF assessment). 6. Disease progression ≥ 5 cm, < LCM, or > 450 cm on imaging (ultrasound, MRI, or CT are acceptable) assessed during screening at any time prior to randomization 3 Baseline splenomegaly defined as having a palpable spleen of volume ≥ 1 7.High risk, intermediate-2 risk, or intermediate-1 risk as defined by DIPSS or DIPSS-plus 8. Do not plan for allogeneic stem cell transplant 9. Acceptable Laboratory Evaluations: [Table 17] 10. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 11. Life expectancy >24 weeks 12.Able to understand and willing to sign the ICF 13. Willing and able to complete PRO assessments using an ePRO device according to the protocol 14. WOCBP, men with partners of childbearing potential, and subjects with pregnant or lactating partners must agree to follow the contraception requirements of the clinical trial protocol from the first dose of MMB throughout the study and for 6 months after the last dose of MMB.

[0212] Exclusion criteria: 1. Use the following measures within the indicated time periods (criteria a-i): a. Anytime MMB b. JAK inhibitor treatment within 2 weeks prior to randomization (see Inclusion Criteria #5) c. Active anti-MF treatment within 2 weeks prior to randomization. Supportive care including steroids for non-MF indications may be used. d. Strong cytochrome P4503A4 (CYP3A4) inducers within 1 week prior to randomization e. Investigational drug within 4 weeks prior to randomization f. Erythropoietin-producing anti-inflammatory drugs (ESAs) within 4 weeks prior to randomization g. Danazol within 3 months prior to randomization h. Splenic irradiation within 3 months prior to randomization i. Current treatment with simvastatin, atorvastatin, lovastatin, or rosuvastatin 2. History of prostate cancer, except for localized prostate cancer treated surgically or treated with therapeutic radiation therapy and presumed cured 3. Prostate-specific antigen (PSA) > 4ng / mL 4. Unsuitable for spleen volume measurement because of previous splenectomy or unwillingness or inability to undergo MRI or CT scan for spleen volume measurement 5. One of the following (criteria a-k): a. Uncontrolled intercurrent illnesses, including but not limited to, uncontrolled active infections (subjects who are under control or receiving outpatient antibacterial and / or antiviral treatment as infection prevention may be included in the study) b. Serious active or chronic bleeding events of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 within 4 weeks prior to randomization c. Unstable angina within 6 months prior to randomization d. Symptomatic congestive heart failure within 6 months prior to randomization e. Uncontrolled cardiac arrhythmia within 6 months prior to randomization f. QTcF interval >500 ms unless due to bundle branch block g. Current ongoing thrombosis despite treatment H. History of porphyria i. Child-Pugh score of 10 or more j. Psychiatric, social, or any other condition that may limit compliance with study requirements or that, in the opinion of the investigator or sponsor, may interfere with interpretation of the study results. k. Unable or unwilling to comply with protocol restrictions regarding MF treatment and other medications prior to and during study treatment. 6. Subjects with a prior or concurrent malignancy whose natural history or treatment may be of significant potential to interfere with the evaluation of the safety or efficacy of the investigational regimen. 7. Known clinically significant anemia due to iron, vitamin B12, or folate deficiency, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding 8. Known positive HIV status 9. Chronic and active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier (testing required for hepatitis B and C) 10. Unresolved non-hematologic toxicity from prior treatment, greater than grade 1 per CTCAE v5.0 11.Presence of peripheral neuropathy grade 2 or higher according to CTCAE v5.0 12. Women who are already pregnant or breastfeeding 13. Known intolerance or hypersensitivity to MMB or DAN, their metabolites, or formulation excipients. 14. Patients with galactose intolerance, Lapp lactase deficiency, or rare genetic problems of glucose-galactose malabsorption. Note: DAN capsules contain lactose.

[0213] Doses and administration forms of investigational product, reference treatment, and placebo: MMB and DAN placebo or DAN and MMB placebo are orally self-administered at approximately the same time every day, regardless of food.The starting dose of MMB is 200 mg, preferably administered in the morning.The starting dose of DAN is 600 mg total daily dose.Blind and open-label treatment with MMB or DAN may be tapered as necessary, and may be interrupted and / or reduced due to thrombocytopenia, neutropenia, or other toxicity according to protocol-specified criteria.

[0214] The starting MMB dose in this study is 200 mg. This dose resulted in clinical improvement of splenomegaly, systemic symptoms, and anemia benefits and was well tolerated over long-term use without the significant drug-related safety concerns observed in the Phase 3 SIMPLIFY study. The starting DAN dose in this study is a total daily dose of 600 mg. Subjects continuing open-label DAN treatment through week 48 receive a reduced dose of 400 mg total daily dose and may be tapered gradually to the minimum dose required to maintain response. Study treatment doses are reduced due to treatment-related toxicity.

[0215] Treatment duration: The randomized treatment period is 24 weeks. Open-label extension treatment with MMB (for those randomized to MMB) or crossover with treatment with MMB (for those randomized to receive DAN) may continue until the end of 204 weeks, i.e., a total treatment period of approximately 4 years. The maximum length of participation in the study, including screening, randomized treatment, open-label extension treatment, and follow-up periods, is approximately 7 years.

[0216] Transition into the MMB extension study, if available, may occur once subjects have completed at least 48 weeks on study.

[0217] Evaluation criteria: Primary Endpoint: MFSAF TSS response rate at week 24. TSS response rate is defined as the proportion of subjects achieving a ≥ 50% reduction in TSS compared to baseline over the 28 days immediately preceding the end of week 24. [Table 18]

[0218] Secondary endpoints (omitted): Proportion of subjects with TI status at the end of 24 weeks; defined as not requiring RBC transfusion (except in cases of clinically evident bleeding) for 12 weeks or more immediately preceding the end of 24 weeks and having an Hgb level of 8 g / dL or greater.

[0219] SRR; defined as the proportion of subjects showing a splenic response (≥35% reduction in spleen volume from baseline at the end of 24 weeks)

[0220] Other secondary endpoints include measures of anemia benefit and duration of response, mean change from baseline MFSAF TSS, safety assessments, survival analyses, change from baseline in PROs, and plasma concentrations of MMB.

[0221] Exploratory endpoints (abbreviation): Exploratory endpoints include time to splenic progression and other endpoints.

[0222] Definition: Myelofibrosis Symptom Assessment Morphologic Total Symptom Score (MFSAF TSS): Symptoms: MFSA TSS of 10 units or more as assessed by MFSAFv4.0 at screening examination. Baseline MFSAF TSS: Mean daily MFSAF TSS for 7 consecutive days (BL days 1 to BL days 7) immediately prior to randomization. MFSAF TSS Response: A 50% reduction in MFSAF TSS at week 24 compared to baseline, i.e., the average of daily TSS from 28 consecutive days prior to the end of the 24 week period.

[0223] Splenic Reaction and Progression: Spleen response: ≥35% reduction in spleen volume from baseline. Confirmed splenic progression: Defined as meeting both of the following criteria: Worsening early satiety accompanied by weight loss of Grade 2 or greater (i.e., 10% or more from baseline) or persistent splenic pain secondary to any of the following: - Narcotic pain medications daily for two consecutive weeks, or Increase in daily dose of narcotic analgesic of 50% or more from baseline. · An increase in splenic volume of 15% or more from baseline (with additional magnetic resonance imaging [MRI] or computed tomography [CT] scans to confirm splenic progression).

[0224] anemia: Anemia: For purposes of study eligibility, defined as any of the following: For any subject; received a blood transfusion within 28 days prior to the first day of baseline assessment (BL1) and had a pre-transfusion Hgb <10 g / dL, or For subjects not on ongoing JAK inhibitor therapy at screening; Hgb <10 g / dL during baseline (BL days 1-7), or For subjects on ongoing JAK inhibitor therapy at screening; Hgb <10 g / dL during screening prior to initiation of JAK inhibitor taper Baseline Hgb level: last observed Hgb before randomization, except if RBC transfusion was received within 28 days, in which case pre-transfusion (up to 7 days prior to transfusion) Hgb value was used. Baseline RBC transfusion need: number of units of RBC transfusion required per month; determined from the number of RBC transfusions given in the 8 weeks prior to randomization (Note: transfusion history will be collected for 12 weeks prior to randomization). Transfusion Independence (TI): No need for RBC transfusions (except for clinically evident bleeding) for 12 weeks or more and Hgb levels ≥ 8 g / dL. Transfusion Dependent (TD): Requiring 4 or more units of RBC transfusion 8 weeks prior to randomization. Hgb levels below 9.5 g / dL will be counted towards TD. RBC transfusions given because of clinically evident bleeding or accident / injury (as assessed by the investigator) will not be counted towards TD. Transfusion requirement (TR): Does not meet criteria for TD or TI. Duration of TI response: number of days from the first day of the 12-week period in which TI status was established to the first RBC transfusion (except in cases of clinically evident bleeding) or Hgb level <8 g / dL. Conversion to TI status: For subjects who were TD or TR at baseline, freedom from the need for RBC transfusions (except in cases of clinically overt bleeding) for ≥12 weeks and have an Hgb level ≥8 g / dL. Conversion to TD status: occurrence of a requirement of 4 or more RBC units in the 8 weeks prior to week 24 (and week 48 in the MMB group) for subjects who were TI or TR at baseline. Rate of RBC transfusion: Mean number of RBC units per month not associated with clinically apparent bleeding or accident / injury.

[0225] Leukemic Transformation: Leukemic transformation: 1×10 lasting for more than 2 weeks 9 Bone marrow blast count ≥ 20% or peripheral blood blast content ≥ 20% associated with absolute blast count ≥ 1 / L

[0226] Criteria for dose adjustment or discontinuation Blinded treatment (MMB and placebo or DAN and placebo) and open-label treatment with MMB or DAN will be interrupted and / or reduced due to thrombocytopenia, neutropenia, or other toxicity. If toxicity occurs during the randomized treatment period, doses of both components of study treatment, i.e., MMB and placebo or DAN and placebo, will be reduced according to the following protocol-specified criteria:

[0227] Continuation of study treatment at a reduced dose is preferred to discontinuation of treatment. Dose reductions are by sequential dose reductions except in cases of non-hematologic or other toxicity. Treatment may be interrupted for up to 28 days, including tapering, and then resumed, as described in the next section. If toxicity persists beyond 28 days, treatment may be resumed with sponsor approval. If toxicity recurs, additional treatment interruptions may be made, and sequential dose reductions may be applied if treatment is resumed. Re-escalation is permitted when toxicity resolves or returns to baseline grade. [Table 19]

[0228] Dose Adjustments in Thrombocytopenia Platelet counts will be monitored throughout the study and study treatment doses will be adjusted based on the degree of thrombocytopenia. At the sponsor's discretion, re-escalation will be permitted when toxicity has resolved or returned to baseline grade.

[0229] Splenic progression, leukemic transformation, and disease progression Subjects with documented symptomatic splenic progression or leukemic transformation will discontinue study treatment. Subjects randomized for DAN who discontinue due to documented symptomatic splenic progression may be crossed over to open-label treatment with MMB.

[0230] Study treatment will be discontinued if disease progression or toxicity is observed that, in the opinion of the sponsor, impairs the ability to continue treatment and / or study-specific procedures necessary for safe continuation of treatment.

[0231] Crossover of study treatments Prior to Week 24, subjects will discuss with the investigator or designee whether they would like to receive the open-label MMB after completing all assessments at Week 24. After completing all assessments at Week 24, subjects may receive the MMB during the open-label extension treatment period unless restricted according to study criteria.

[0232] Subjects willing and able to receive open-label MMB may begin open-label MMB at the following time points and continue treatment through the end of Week 204: At the end of 24 weeks if the randomized treatment period and all 24-week assessments were completed. At the end of 24 weeks, if treatment with DAN was discontinued before the end of 24 weeks but the participant continued in study evaluations and did not receive prohibited medications. At any time during the randomized treatment period if the patient met the protocol-defined criteria for symptomatic splenic progression and was confirmed to have undergone randomized treatment with DAN according to the open-label process.

[0233] Upon completion of the randomized treatment period, including all 24-week assessments, subjects who elect to receive open-label MMB and are not restricted by protocol will begin treatment with a starting dose of 200 mg unless the study treatment dose is reduced due to suspected MMB-related toxicity during the randomized treatment period. Dose re-escalation will be permitted at the sponsor's discretion, up to a maximum daily dose of 200 mg MMB, when toxicity has resolved or returned to baseline grade.

[0234] Subjects randomized to receive DAN who receive clinical benefit at the end of 24 weeks and do not cross over to MMB may continue open-label DAN treatment through week 48 at a maximum total daily dose of 400 mg. Subjects who receive a reduced dose of DAN during the randomized treatment period must maintain the reduced dose. During open-label treatment with DAN, the dose may be tapered to the minimum dose required to maintain response. Subjects who elect not to continue open-label MMB or DAN will discontinue study treatment.

[0235] The MOMENTUM trial is a randomized, double-blind, phase 3 study to evaluate the activity of momelotinib (MMB) versus danazol (DAN) in patients with primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis, or post-essential thrombocythemia (ET) myelofibrosis previously treated with JAK inhibitor therapy (MOMENTUM trial). Phase 3 results confirm the clinical benefit of MMB (e.g., as described above) in reducing transfusion burden, and systemic symptoms, splenomegaly, and anemia. The association between anemia benefit and patient-reported measures of clinical benefit has been confirmed by the phase 3 results.

[0236] Although the foregoing invention has been described in some detail by way of illustration and example for clarity of understanding, it will be readily apparent to those skilled in the art that certain changes and modifications can be made to the invention in light of the teachings of the invention without departing from the spirit or scope of the appended claims.

[0237] Thus, the above merely illustrates the principles of the invention. It will be understood that those skilled in the art can devise various arrangements that embody the principles of the invention and are within its spirit and scope, although not expressly described or shown herein. Furthermore, all examples and conditional language recited herein are intended primarily to aid the reader in understanding the principles of the invention and the concepts that the inventors have contributed to advancing the art, and should be construed as not being limited to such specifically recited examples and conditions. Furthermore, all statements herein that describe the principles, aspects, and embodiments of the invention, as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Moreover, such equivalents are intended to include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. Furthermore, nothing disclosed herein is intended to be construed as a public offering, regardless of whether such disclosure is expressly set forth in the claims.

[0238] Therefore, the scope of the present invention is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of the present invention is embodied in the appended claims. In the claims, 35 U.S.C. 112(f) or 35 U.S.C. 112(6) is defined to apply a limitation in a claim only if the precise phrase "means for" or the precise phrase "step for" appears at the beginning of such limitation in the claim, and if such precise phrase is not used in the limitation in the claim, 35 U.S.C. 112(f) or 35 U.S.C. 112(6) is not applicable.

Claims

1. A pharmaceutical composition comprising a therapeutically effective amount of momelotinib or a pharma- ceutical acceptable salt thereof for treating a subject, The subject to be administered is a patient suffering from (i) myelofibrosis and (ii) 150×10 9 1. Identified as having a platelet count of less than 1 / L; The subject receives 50×10 9 maintaining a platelet count above a threshold platelet count of ≥ 100 / L; the subject is identified as having a platelet count of less than 50×10 9 / L; and The therapeutically effective amount is 50 mg / day to 200 mg / day. Pharmaceutical compositions.

2. The object is 50 x 10 9 2. The pharmaceutical composition of claim 1, wherein the patient is identified as having a platelet count of less than 100 / L.

3. 3. The pharmaceutical composition of claim 1 or 2, wherein the platelet count is a baseline platelet count determined within one week prior to the start of momelotinib treatment, and the subject has not been treated with a previous JAK inhibitor therapy for at least two weeks prior to momelotinib treatment.

4. The pharmaceutical composition of any one of claims 1 to 3, further comprising an initial step of determining the level of platelets in a sample from a subject with myelofibrosis.

5. The pharmaceutical composition of any one of claims 1 to 4, wherein the subject has previously been treated with a JAK inhibitor.

6. The pharmaceutical composition of claim 5, wherein the subject has previously been treated with ruxolitinib.

7. 7. The pharmaceutical composition of claim 6, wherein the subject is an adult who has responded inadequately to or is intolerant to ruxolitinib.

8. 7. The pharmaceutical composition of claim 6, wherein the subject has not responded or has become non-responsive to previous ruxolitinib treatment.

9. The pharmaceutical composition of claim 5, wherein the subject has previously been treated with fedratinib.

10. 10. The pharmaceutical composition of claim 9, wherein the subject is an adult who has responded inadequately to or is intolerant to fedratinib.

11. 10. The pharmaceutical composition of claim 9, wherein the subject has not responded or has become non-responsive to previous fedratinib treatment.

12. The pharmaceutical composition of any one of claims 1 to 4, wherein the subject is naïve to JAK inhibitor treatment.

13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the myelofibrosis is intermediate-risk or high-risk myelofibrosis.

14. The pharmaceutical composition of claim 13, wherein the myelofibrosis is intermediate-2 risk or high risk myelofibrosis.

15. The pharmaceutical composition according to any one of claims 1 to 14, wherein the myelofibrosis is primary myelofibrosis (PMF).

16. The pharmaceutical composition according to any one of claims 1 to 14, wherein the myelofibrosis is post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV / ET MF).

17. The pharmaceutical composition according to any one of claims 1 to 16, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is momelotinib dihydrochloride.

18. 18. The pharmaceutical composition of claim 17, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is momelotinib dihydrochloride monohydrate.

19. 19. The pharmaceutical composition of claim 18, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is momelotinib dihydrochloride monohydrate form II.

20. 20. The pharmaceutical composition of claim 19, wherein the momelotinib dihydrochloride monohydrate Form II is in a crystalline form comprising a crystal having unit cell parameters at T=100°K of a=10.2837(6) Å, b=10.4981(6) Å, c=11.5143(7) Å, α=83.297(2)°, β=87.649(2)°, y=67.445(2)°, and the triclinic P-1 space group.

21. 20. The pharmaceutical composition of claim 19, wherein the momelotinib dihydrochloride monohydrate Form II is characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG.

19.

22. 20. The pharmaceutical composition of claim 19, wherein the momelotinib dihydrochloride monohydrate Form II is characterized by an X-ray powder diffraction (XRPD) pattern with peaks at about 7.7°, 19.3°, 24.0°, 25.7°, and 29.6° 2-θ ± 0.2° 2-θ.

23. 20. The pharmaceutical composition of claim 19, wherein the momelotinib dihydrochloride monohydrate Form II is characterized by a differential scanning calorimetry (DSC) pattern substantially as shown in Figure 22.

24. 20. The pharmaceutical composition of claim 19, wherein the momelotinib dihydrochloride monohydrate Form II is characterized by a dynamic vapor sorption (DVS) pattern substantially as shown in Figure 28.

25. The pharmaceutical composition of any one of claims 1 to 24, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is administered orally.

26. The pharmaceutical composition of any one of claims 1 to 25, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is administered daily.

27. 27. The pharmaceutical composition of claim 26, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is administered once daily.

28. The pharmaceutical composition according to any one of claims 1 to 27, wherein the therapeutically effective amount is 200 mg / day.

29. The pharmaceutical composition according to any one of claims 1 to 27, wherein the therapeutically effective amount is 150 mg / day.

30. The pharmaceutical composition according to any one of claims 1 to 27, wherein the therapeutically effective amount is 100 mg / day.

31. The pharmaceutical composition according to any one of claims 1 to 27, wherein the therapeutically effective amount is 50 mg / day.

32. A pharmaceutical composition comprising a therapeutically effective stable dose of momelotinib or a pharma- ceutical acceptable salt thereof, The subject to be administered has myelofibrosis and is administered the therapeutically effective stable dose of momelotinib or a pharma- ceutical acceptable salt thereof for a treatment period; the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the treatment period; The subject receives 50×10 9 / L or more threshold platelet count, the subject is identified as having a platelet count of less than 50×10 9 / L; and The therapeutically effective amount is 50 mg / day to 200 mg / day. Pharmaceutical compositions.

33. 33. The pharmaceutical composition of claim 32, wherein the stable dose is 200 mg / day.

34. 34. The pharmaceutical composition of claim 33, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is administered orally.

35. 35. The pharmaceutical composition of claim 33 or 34, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is administered once daily.

36. The pharmaceutical composition of any one of claims 32 to 35, wherein the subject has previously been treated with a JAK inhibitor.

37. 37. The pharmaceutical composition of claim 36, wherein the subject has previously been treated with ruxolitinib.

38. 38. The pharmaceutical composition of claim 37, wherein the subject is an adult who has had an inadequate response to or is intolerant to ruxolitinib.

39. 38. The pharmaceutical composition of claim 37, wherein the subject has not responded or has become non-responsive to previous ruxolitinib treatment.

40. 37. The pharmaceutical composition of claim 36, wherein the subject has previously been treated with fedratinib.

41. 41. The pharmaceutical composition of claim 40, wherein the subject is an adult who has responded inadequately to or is intolerant to fedratinib.

42. 41. The pharmaceutical composition of claim 40, wherein the subject has not responded or has become non-responsive to previous fedratinib treatment.

43. The pharmaceutical composition of any one of claims 32 to 35, wherein the subject is JAK inhibitor treatment naive.

44. The pharmaceutical composition according to any one of claims 32 to 43, wherein the myelofibrosis is intermediate-risk or high-risk myelofibrosis.

45. The pharmaceutical composition of claim 44, wherein the myelofibrosis is intermediate-2 risk or high risk myelofibrosis.

46. The pharmaceutical composition according to any one of claims 32 to 45, wherein the myelofibrosis is primary myelofibrosis (PMF).

47. The pharmaceutical composition according to any one of claims 32 to 45, wherein the myelofibrosis is post-polycythemia vera or post-essential thrombocythemia myelofibrosis.

48. The pharmaceutical composition of any one of claims 32 to 47, wherein said momelotinib or a pharma- ceutically acceptable salt thereof is momelotinib dihydrochloride.

49. 49. The pharmaceutical composition of claim 48, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is momelotinib dihydrochloride monohydrate.

50. 50. The pharmaceutical composition of claim 49, wherein the momelotinib or a pharma- ceutically acceptable salt thereof is momelotinib dihydrochloride monohydrate form II.

51. 51. The pharmaceutical composition of claim 50, wherein the momelotinib dihydrochloride monohydrate Form II is in a crystalline form comprising a crystal having unit cell parameters at T=100°K of a=10.2837(6) Å, b=10.4981(6) Å, c=11.5143(7) Å, α=83.297(2)°, β=87.649(2)°, y=67.445(2), and the triclinic P-1 space group.

52. 51. The pharmaceutical composition of claim 50, wherein the momelotinib dihydrochloride monohydrate Form II is characterized by an X-ray powder diffraction (XRPD) pattern substantially as shown in FIG.

19.

53. 51. The pharmaceutical composition of claim 50, wherein the momelotinib dihydrochloride monohydrate Form II is characterized by an X-ray powder diffraction (XRPD) pattern with peaks at about 7.7°, 19.3°, 24.0°, 25.7°, and 29.6° 2-θ ± 0.2° 2-θ.

54. 51. The pharmaceutical composition of claim 50, wherein the momelotinib dihydrochloride monohydrate Form II is characterized by a differential scanning calorimetry (DSC) pattern substantially as shown in Figure 22.

55. 51. The pharmaceutical composition of claim 50, wherein the momelotinib dihydrochloride monohydrate Form II is characterized by a dynamic vapor sorption (DVS) pattern substantially as shown in FIG.

28.

56. The subject receives 100×10 9 56. The pharmaceutical composition of any one of claims 32 to 55, wherein the pharmaceutical composition maintains a platelet count above a threshold platelet count of 100 / L or more.

57. The subject receives 150×10 9 57. The pharmaceutical composition of any one of claims 32 to 56, wherein the pharmaceutical composition maintains a platelet count of less than 100 / L.

58. The subject receives 150×10 9 57. The pharmaceutical composition of any one of claims 32 to 56, wherein the pharmaceutical composition maintains a platelet count above a threshold platelet count of 100 / L or more.

59. The subject receives 200×10 9 59. The pharmaceutical composition of claim 58, wherein the platelet count is maintained above a threshold platelet count of at least 100 / L.

60. The subject receives 250×10 9 59. The pharmaceutical composition of claim 58, wherein the platelet count is maintained above a threshold platelet count of at least 100 / L.

61. The pharmaceutical composition of any one of claims 32 to 60, wherein the treatment period is 12 weeks or longer.

62. 62. The pharmaceutical composition of claim 61, wherein the treatment period is 24 weeks or longer.

63. 62. The pharmaceutical composition of claim 61, wherein the treatment period is 36 weeks or longer.

Citation Information

Patent Citations

  • Therapies for treating myeloproliferative disorders

    JP2016537433A

  • n-(Cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride

    JP2017517535A